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PART I. Enhanced intestinal absorption of indinavir and its 
metabolic conversion to M6 by the co-administration of HM-
30181A, a P-glycoprotein inhibitor
Intestinal P-glycoprotein (P-gp), an efflux transporter, may render its 
substrate to ‘recycle’ during the intestinal absorption process. The objective of 
this study is to determine the contribution of P-gp mediated ‘recycling’ in the 
intestinal first pass metabolism. To examine whether HM-30181A, a 
II
potentially specific inhibitor for P-gp, interacted with CYP enzymes (i.e., 1A2, 
2C9, 2C19, 2D6, 3A4), the metabolic stability of standard substrates for major 
CYP enzymes in rat liver microsomes was studied in the presence and the 
absence HM-30181A. Furthermore, to determine whether compound 
interacted with typical SLC transporters (i.e., rOatp1b2, rOat1, rOat3 and 
rOct2), the uptake of their standard substrates in MDCKII/FRT cells 
expressing the transporters was studied with or without the compound. In this 
study, indinavir was selected as the model compound since the drug is a well-
established substrate for both P-gp and CYP3A4. Rats orally received the 
dose of 10 mg/kg of HM-30181A, 10 minutes prior to the indinavir 
administration (10 mg/kg orally). For portal vein infusion study, rats received 
indinavir infusion via portal vein catheter at the rate of 15 mg/kg/h for 20 min 
while the inhibitor was given orally 10 min prior to the initiation of the 
infusion. It was found that HM-30181A did not affect the activity of typical 
CYP enzymes (1A2, 2C9, 2C19, 2D6 or 3A4) and SLC transporters 
(rOatp1b2, rOat1, rOat3, rOct2) suggesting that the compound was a specific 
inhibitor for P-gp. In oral administration study, Cmax values of indinavir (Cmax, 
IND) for control and HM30181-treated group were (in mean ± SD) 0.614 ± 
0.083 and 1.51 ± 0.64 μg/mL, respectively. AUC values for indinavir (AUCIND) 
of the two groups were also affected similarly [viz, in HM-30181 treated 
group, AUC approximately 111% higher (p<0.05) than control group]. AUC 
of M6 (AUCM6) was increased in HM-30181A-treated group to the similar 
extent of the increase found with AUCIND. For the case of portal vein infusion 
III
study, Cmax, IND, AUCIND and AUCM6 were 1.4, 2.5 and 1.9-fold increased when 
HM-30181A was co-administered. In Ussing chamber study, Papp values 
were 2.85 ± 0.19 and 4.34 ± 1.08 X 10-6 cm/sec for untreated and HM-
30181A treated group, respectively. Amount of indinavir was tend to increase 
(2650 ± 1130 and 3290 ± 1110 pmole/g tissue, respectively), although the 
values were not statistically different. For the case of M6 conversion, the 
amount of the metabolite was increased (54.9 ± 10.9 and 77.3 ± 16.3 pmole/g 
tissue, respectively, p < 0.05) in the intestine when the tissue was treated with 
HM-30181A, consistent with a simulation result with a kinetic model 
assuming cooperative action of recycling and metabolism. Therefore, the in 
vivo observations with different routes of indinavir administration, ex vivo 
study and in silico study collectively showed that the absorption and 
metabolism of indinavir is slightly enhanced by HM-30181A. 
PART II. Quantification of EC-18, a synthetic 
monoacetyldiglyceride (1-palmitoyl-2-linoleoyl-3-acetyl-rac-
glycerol), in rat and mouse plasma by liquid-
chromatography/tandem mass spectrometry
EC-18 (i.e., 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol), an active 
ingredient in Rockpid®, has been reported to be useful in controlling various 
types of inflammations, particularly those caused by neutropenia. Although 
this product was originally approved as a functional food in Korea, it is 
IV
currently in phase II clinical trials for use in managing the severe 
chemotherapy-induced neutropenia in patients with advanced breast cancer 
who are receiving intermediate febrile neutropenia risk chemotherapy. The 
objective of this study was to develop a rapid, sensitive method for the 
determination of EC-18 in rat and mouse plasma and to evaluate the 
applicability of the assay in pharmacokinetic studies. EC-18 was extracted 
with MeOH from rat and mouse plasma samples, and the extract directly 
introduced onto an LC-MS/MS system. The analyte and EC-18-d3, an internal 
standard, were analyzed by multiple reaction monitoring (MRM) at m/z 
transitions of 635.4→355.4 for EC-18 and 638.4→338.4 for the internal 
standard, respectively. The lower limit of quantification (LLOQ) was 
determined at 50 ng/mL, with an acceptable linearity in the range from 50 to 
10000 ng/mL (r > 0.999) for both matrices. Validation parameters such as 
accuracy, precision, dilution, recovery, matrix effects and stability were found 
to be within the acceptance criteria of the assay validation guidelines, 
indicating that the assay is applicable for estimating EC-18 in concentrations 
in the range examined. EC-18 was readily determined in plasma samples for 
periods of up to 8 h following an intravenous bolus injection of 1 mg/kg in 
rats and at 5 mg/kg in mice, respectively, and up to 24 h following the oral 
administration of 2000 mg/kg in mice. The findings indicate that the current 
analytical method is applicable for pharmacokinetic studies of EC-18 in small 
animals.
V
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INTRODUCTION
Oral administration of drugs is probably the most popular way of 
administration because of its convenience, economy and relative safety. 
Despite these advantages, however, complications, such as inadequate 
solubility of active ingredient in gastric/intestinal fluids and instability in the 
intestine do exist so that, in some cases, the rate and extent intestinal 
absorption be altered/limited significantly (Higuchi et al., 1981; Ho et al., 
1983). In addition to these complications, various biological / physiochemical 
factors such as food, gastric and intestinal transit time, membrane 
permeability, intestinal pH and mesenteric blood flow rate may affect its 
intestinal absorption (Benet et al., 1996). As an example of the complexity of 
intestinal absorption of drugs, it is well known that the absorption of 
tetracycline hydrochloride was significantly decreased with iron, milk or food 
in healthy volunteer (Leyden, 1985). In addition, the bioavailability of 
celecoxib was much higher when given as a solution compared with a capsule 
(Paulson et al., 2001), indicating that the physical form of the formulation also 
affects the intestinal absorption.
One of the most widely recognized problems in the intestinal drug 
absorption is pre-systemic first pass effect in the intestine and/or in the liver 
(Thummel et al., 1997; Lin et al., 1999a): Metabolism during the transport 
across the intestinal epithelium and through the liver may occur so that the 
amount of drug reaching the systemic circulation may be comparatively less. 
２
As examples to the importance of pre-systemic elimination, baicalein and 
metoprolol, compounds having adequate permeability across the small 
intestine, had low bioavailability due to hepatic first pass effect (Zhang et al., 
2005; Yoon et al., 2011). In addition to the metabolic enzymes affecting the 
extent of absorption, drug transporters may be involved in intestinal 
absorption of some drugs. During 1990s’, the molecular characteristics of 
drug transporters from animals and humans has been extensively studied 
(Elferink et al., 1995; Meijer et al., 1997; Müller and Jansen, 1998; Kim et al., 
2000): From these studies, it is now well recognized that not only the 
physicochemical properties but also the affinity toward drug transporter(s) 
may be a factor in the intestinal absorption for certain drugs. For added 
complexity in understanding drug absorption in the intestine, efflux 
transporters [e.g., MDRs and MRPs; (Kool et al., 1997; Watkins, 1997)] that 
pump their substrates back into the lumen are reported be expressed in the 
intestine, in addition to the influx transporters [e.g., OATs, OATPs and OCTs 
(Koepsell, 1998; Sekine et al., 1999; Tamai et al., 2000); transporters that 
enhances the intestinal drug absorption]. For example, exposure of 
rosuvastatin (an OATP2B1 substrate) was approximately markedly decreased 
with ronacaleret (an OATP2B1 inhibitor) (Johnson et al., 2016), suggesting 
importance of transporters in the intestinal absorption of certain drugs. In 
addition, the intestinal absorption of cyclosporine A (an MDR1 substrate) was 
significantly increased in MDR1 gene knockout mouse (Lee et al., 2005). 
Amongst these, P-glycoprotein (MDR1) is one of the most extensively studied 
３
efflux transporters. This ATP-binding cassette transporter is reported to be 
expressed in the apical membrane of the villus tip of gut enterocyte, and 
transports the substrate back to the luminal side (Watkins, 1997). Interestingly, 
although it is still highly controversial, the concerted action of the efflux 
transporter and the drug metabolizing enzyme was reported so that the 
absorption time may be prolonged by the action of the efflux transporter 
thereby leading to an enhanced chance for metabolic reaction (Johnson et al., 
2001; Cummins et al., 2002; Cummins et al., 2003). On the contrary, however, 
in/ex vivo studies, along with theoretical analysis, seems to suggested a 
decreased metabolism for the dual substrates by the involvement of P-gp in 
the intestine. (Lan et al., 2000; Tam et al., 2003). In part I of this thesis, the 
interplay between P-glycoprotein and CYP3A4 was studied with indinavir, a 
common substrate for the transporter and the enzyme by using HM-30181A, a 
potentially specific inhibitor of the efflux transporter.
Other complication during intestinal drug absorption would be the 
possibility of the chemical loss of the active ingredient in the gastrointestinal 
lumen by the decomposition. In general, active ingredient is dissolved from 
the dosage from depending on its physicochemical/pharmaceutical properties. 
Since the rate/extent of absorption is a function of the amount/concentration 
of the drug in the intestine, the instability in the intestine would be one of the 
key factors in determining the oral bioavailability. The intestinal stability may 
be dependent on various reactions in the intestine, enzymatic or non-
４
enzymatic. For example, acid hydrolysis of penicillin G may occur in the 
stomach thereby leading to a loss of activity (György et al., 1945). Enzymatic 
reaction caused by digestive enzymes (e.g., in the pancreatic fluid), metabolic 
enzyme and enzymes from microflora may affect the stability of drugs in the 
intestine. For example, intestinal esterases hydrolyzed ester-type drugs such 
as aspirin, clofibrate, indanyl carbenicillin and procaine (Inoue et al., 1980). 
In addition, the absorption of glycerol and glycerides may undergo a 
complicated enzymatic reactions, as evidenced by their rapid decomposition 
during the digestion / absorption processes (Senior, 1964; Humberstone and 
Charman, 1997). Therefore, the limitation of bioavailability of a 
monoacetyldiglyeride, EC-18, by its intestinal instability, potential caused by 
intestinal esterase(s), was studied in part II of the thesis.
５
PART I
Enhanced intestinal absorption of indinavir and 
its metabolic conversion to M6 by




It is now well established that the intestinal P-glycoprotein (P-gp), an 
efflux transporter, limits the absorption of variety of drugs (Wacher et al., 
1998; Lee et al., 2005; Murakami and Takano, 2008). For example, the AUC 
of orally administered imatinib, a P-gp substrate, was increased approximately 
3 to 4-fold when elacridar and pantoprazole, both P-gp substrates were co-
administered (Oostendorp et al., 2009). In addition, some food substances 
such as grapefruit juice may strongly inhibit the action of the efflux 
transporter thereby leading to a significant increase in the absorptive transport 
of P-gp substrates (e.g., talinolol) in Caco-2 monolayers (e.g., talinolol) 
(Spahn-Langguth and Langguth, 2001).
While it was originally thought that compounds with hydrophobic 
amine were primarily subjected to the efflux transport by P-gp (Bönisch et al., 
1978), it is now increasingly evident that the substrate specificity is much 
wider for the transporter so that certain neutral / acidic compounds may also 
be the substrate (Putnam et al., 2002) to the transporter. Interestingly, CYP 
metabolizing enzymes, particularly CYP3A, also possess wide substrate 
specificity and, as a result, a significant portion of P-gp substrates may also be 
the substrate to the metabolizing enzymes as well. Theoretically, P-gp may 
render the dual substrates to ‘recycling’ during their absorption thereby 
leading to the prolongation of mean absorption time and to the enhancement 
７
in intestinal metabolism. However, the experimental observation on the 
pharmacokinetic impact for the shared specificity appeared to be quite 
controversial. For example, it was proposed that, for a drug subjected to both 
P-gp mediated transport and CYP3A metabolism, the action of the efflux 
transporter may render the enhanced intestinal first pass metabolism of the 
drug by prolonging the mean absorption time (Johnson et al., 2001; Cummins 
et al., 2002; Cummins et al., 2003). On the contrary, however, others found 
that P-gp decreased metabolism of the dual substrate in the intestine in in/ex 
vivo study or theoretical analysis (Lan et al., 2000; Tam et al., 2003). 
Furthermore, other examples indicate that P-gp had little or no significant 
effect on intestinal first pass metabolism (Kato et al., 2003; Dufek et al., 
2013). Currently, the underlying reason(s) for the complicated outcome is (are) 
not known. In the literature, however, the experimental design, particularly 
the use of P-gp / CYP3A inhibitor, was not consistent amongst the studies so 
that the results may not be directly compared. Furthermore, even for the 
studies using P-gp deficient mice to address the interplay between P-gp and 
CYP, the possibility of compensatory mechanism was not adequately 
examined (van Waterschoot and Schinkel, 2011).
Some of the discrepancies in the study of the ‘recycling’ on the 
intestinal first pass effect of drugs that are substrates for both the metabolizing 
enzymes and the efflux transport are likely to be originated from the lack of 
specific inhibitor of P-gp. HM-30181A, 4-oxo-4H-chromene-2-carboxylic 
８
acid, [2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoqui-nolin-2-yl)-ethyl]-
phenyl}-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl]amide, was recently 
developed as a P-gp inhibitor to enhance the  oral bioavailability of 
paclitaxel (Paek et al., 2006b). The new P-gp inhibitor was relatively potent 
and apparently selective in comparison to other P-gp inhibitors such as 
cyclosporine A, XR9576 and GF120918 (Kwak et al., 2010). Unfortunately, 
however, the possibility of the inhibitor for CYP mediated metabolism was 
not previously examined. Furthermore, the impact of the compound on the 
function of SLC transporters is not known. The objectives of this study, 
therefore, were two-fold: to determine the effect of HM-30181A on the 
activities of major CYP isozymes / SLC transporters, and to study the 
contribution of P-gp recycling in the intestinal first pass metabolism of a 
model substrate for P-gp and CYP3A using HM-30181A. In this study, 
indinavir was selected as a model substrate since the antiviral agent is known 
to have an extremely high efflux ratio (e.g., 15 in Caco-2 cell monolayer) due 
to the action of P-gp (Rouquayrol et al., 2002) while it is primarily 
metabolized by CYP3A (Lin et al., 1996). The formation of M6, an N-
depyridomethylated metabolite of indinavir [viz, 33 ~ 58% of the total 
metabolites (Lin et al., 1996), was also monitored as an index of the first pass 
effect in this study.
９
2. Materials and Methods
2.1 Chemicals and reagents
Indinavir, citric acid, formic acid, potassium phosphate monobasic, 
Hanks’ balanced salts (HBSS), sodium bicarbonate, D-(+)-glucose, HEPES, 
glipizide [an internal standard (IS) in indinavir assay], phenacetin, diclofenac 
sodium salt, omeprazole, dextromethorphan, ketoconazole, (±)-metoprolol 
(+)-tartrate salt and N,N-dimethylacetamide (DMAc) were purchased from 
Sigma-Aldrich (St. Louis, MO). The metabolite of indinavir (M6; N-[2(R)-
hydroxy-l(S)-indanyl]-5-[2(S)-(1,1-dimetyl-ethylaminocarbonyl)piperizin-1-
yl]-4(S)-hydroxy-2(R)-phenylmethyl pentanamide) was synthesized in-house 
from indinavir. HM-30181A was generously provided by Hanmi Pharm. Co., 
Ltd. (Seoul, Korea). Testosterone was purchased from Tokyo Chemical 
Industry Co. (Tokyo, Japan). [3H] Digoxin (29.8 Ci/mmol) and [14C] mannitol 
(57.1 mCi/mmol) were obtained from PerkinElmer (Waltham, MA). 
Dulbecco’s modified Eagle’s medium (DMEM), non-essential amino acid 
solution (NEAA), Dulbecco’s phosphate buffered saline (DPBS), penicillin-
streptomycin and fatal bovine serum (FBS) were also obtained from 
WelGENE (Gyeongsangbuk-do, Korea). Polyethylene glycol 400 (PEG 400) 
[Duksan Pure Chemicals (Gyeonggi-do, Korea)] was also used in this study. 
Caco-2 cells were obtained from American Type Culture Collection 
(Rockville, MD). MDCKII cells were provided by Dr. Borst in the Netherland 
Cancer Institute (Amsterdam, Netherland). Collagen-coated Transwell®
１０
inserts (0.4 μm membrane pore size, 1.12 cm2 surface area; product no. 3493) 
were purchased from Corning Inc. (Kennebunk, ME). Pooled male rat liver 
microsomes and nicotinamide adenine dinucleotide phosphate oxidase 
(NADPH) regenerating system solutions were purchased from Corning 
Gentest (Woburn, MA). Zoletil (Tiletamine-HCl/zolazepam-HCl) was 
obtained from Virbac Laboratories (Carros, France) or Rompun (xylazine-HCl) 
from Bayer Corp. (Shawnee Mission, KS). Solvents were of HPLC grade and 
obtained from Fisher Scientific (Pittsburgh, PA). All chemicals were used 
without further purification.
2.2 Animals
Male Sprague-Dawley (SD) rats, weighing 250 to 350 g, were used in 
this study (Orient Bio Inc., Gyeonggi-do, Korea) and maintained on a 12 h 
light/dark cycle with free access to food and water at the Seoul National 
University Institutional Animal Care Facility and acclimatized for at least 3 
days before studies. Animals used in all studies were fasted 24 h. When it was 
necessary to anesthetized rats, the animals received tiletamine/zolazepam (20 
mg/mL) and xylazine (4 mg/mL) solution at a dose of 1 mL/kg by 
intramuscular administration. All studies were reviewed and approved by the 
Seoul National University Institutional Animal Care and Use Committee 
according to the National Institutes of Health Publication Number 85-23 
Principles of Laboratory Animal Care revised in 1985.
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2.3 In vitro Studies
2.3.1. Potential Inhibition of CYP-mediated Metabolisms by HM-30181A 
in Rat Liver Microsomal Incubations
The potential of HM-30181A for inhibiting major rat CYP enzymes 
(1A2, 2C9, 2C19, 2D6 and 3A4) was studied in a system consisting of rat 
liver microsomes (RLMs) and NADPH regenerating system. The reaction 
mixture (final volume of 1 mL) consisted of 0.5 mg/mL RLMs, 10 μM HM-
30181A in a vehicle (DMAc:PEG400:saline = 1:2:1), 0.1 M potassium 
phosphate (pH 7.4), 1.3 mM NADP+, 3.3 mM glucose-6-phosphate, 0.4 U/mL
glucose-6-phosphate dehydrogenase and 3.3 mM MgCl2. After equilibrated at 
37˚C for 10 min, reaction was initiated by adding substrate [i.e., 10 μM 
phenacetin (1A2), 5 μM diclofenac (2C9), 1 μM omeprazole (2C19), 1 μM 
dextromethorphan (2D6), or 30 μM testosterone (3A4)] for major CYPs. The 
final concentration of each substrate was lower than reported Km in RLMs 
(Kuntzman et al., 1965; Kerry et al., 1993; Bogaards et al., 2000; Easterbrook 
et al., 2001; Lee et al., 2007). The mixture was incubated in water bath at 
37˚C and samples (100 μL) were collected at 0, 5 and 10 min (for the study of 
the involvement of CYP3A4) or 0, 5, 10 and 15 min (2C9, 2C19 and 2D6) or
0, 20, 40 and 60 min (1A2). The sample was then added with 100 μL of ice-
cold acetonitrile to terminate the reaction. After vortexing for 10 min, samples 
were centrifuged at 16,100 g in 4˚C for 5 min. The concentration of the 
substrates in the supernatant from samples was measured using UV/LC 
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system (see below).
2.3.2. Potential Inhibition of SLC Transporters by HM-30181A in 
MDCKII/FRT cells Expressing the Transporters
To determine the interaction of HM-30181A with typical SLC 
transporters [organic anion transporting polypeptide 1b2 (rOatp1b2, 
orthologous form for hOATP1B1 and hOATP1B3 in human), organic anion 
transporter 1, 3 (rOat1, rOat3) and organic cation transporter 2 (rOct2)] were 
cloned and functionally expressed in MDCKII/FRT cells containing Flip-In 
system (Invitrogen, Carlsbad, CA) (Lee et al., 2015). Transfected 
MDCKII/FRT cells were seeded onto 24-well plates at a density of 500,000 
cells/mL and were grown in Dulbecco’s modified Eagle medium (DMEM, 
with 1 g/L of D-glucose) with 10% (v/v) fetal bovine serum (FBS), 1% (v/v) 
non-essential amino acid (NEAA), 100 units/mL penicillin/streptomycin and 
10 mM HEPES. Seeded cells were placed in a humidified incubator at 37℃
and 5% CO2. After two days, the cells were washed three times and pre-
incubated with transport media (TM, adjusted to pH 7.4 with sodium 
hydroxide). In this study, TM was consisted of 9.7 g/L HBSS, 2.38g/L HEPES 
and 0.35 g/L sodium bicarbonate. After 10 min, the medium was removed and 
replaced with the media containing the substrate [i.e., [3H] estrone-3-sulfate 
(E3S; total concentration of 1 μM containing 3% labelled compound; 
substrates for rOatp1b2 and rOat3), [3H] p-aminohippuric acid (PAH; total 
concentration of 2 μM containing 10% labelled compound; substrate for rOat1) 
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and [3H] 1-methyl-4phenylpyridium (MPP+; total concentration of 1 μM 
containing 0.5% labelled compound; substrate for rOct2)] with or without 
corresponding inhibitor [i.e., atorvastatin (50 μM, rOatp1b2), probenecid (500 
μM, rOat1 and rOat3), or diphenhydramine (300 μM, rOct2)]. When it was 
necessary, HM-30181A (100 μM) replaced the standard inhibitors for the 
transporters to study the potential inhibition of the transporters. In this study, 
the cells were incubated for 5 min to study the cellular accumulation (i.e, the 
uptake) of the substrate. Upon completion of the incubation, the medium was 
aspirated and cells washed three times with ice-cold Dulcecco’s phosphate 
buffered saline (DPBS). After solubilization of cells with 0.2 N NaOH, the 
lysate was added with Ultima Gold (PerkinElmer, Waltham, MA) and the 
amount of substrate in the sample determined by liquid scintillation counter 
(Tri-Carb 3110 TR, PerkinElmer Life Science, Boston, MA). The uptake rate 
were normalized by protein concentration as determined by bicinchoninic acid 
(BCA) assay.
2.3.3. Transport of M6 in Caco-2 Cell Monolayers
When it was necessary to study whether M6, the major metabolite of 
indinavir in rats, is subjected to P-gp mediated transport, bi-directional 
transport of M6 were studied with or without verapamil (i.e., standard P-gp 
inhibitor) or HM-30181A in Caco-2 cells. In this study, the transport of [3H] 
digoxin (standard P-gp substrate), [14C] mannitol (low permeability marker) 
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or (±)-metoprolol (+)-tartrate salt (high permeability marker) were used as a 
standard compound in the cell monolayer. Caco-2 cells with passage number 
43 were seeded onto 12-well collagen coated Transwell® at the density of 
500,000 cells/mL and were grown in DMEM (with 4.5 g/L D-glucose) with 
20% (v/v) FBS, 1% (v/v) NEAA, 1% (v/v) penicillin-streptomycin. Cells 
were, then, placed in a humidified incubator at 37℃ and 5% CO2 and the 
culture medium was replaced every two days. After 7 days, FBS concentration 
was changed to 10% (v/v). All bi-directional transport studies were conducted 
21 days after seeding. Trans-epithelial electric resistance (TEER) was 
measured by Epithelial Voltohmmeter (EVOM, World Precision Instruments, 
Sarasota, FL) after washing cells three times with TM [9.7 g/L HBSS, 0.35 
g/L sodium bicarbonate, 2.38 g/L HEPES, 1.95 g/L glucose, pH 7.35]. In this 
study, TEER value between 252 and 382 Ω∙cm2 was used (Press, 2011).
When it was necessary to study the transport of compounds from the 
apical side to basolateral side, donor solution (0.5 mL) containing [3H] 
digoxin (1 μM), [14C] mannitol (100 μM), metoprolol (50 μM) or M6 (10 μM) 
in the presence or the absence of the inhibitor (i.e., HM-30181A or verapamil) 
was added to the apical side while 1.5 mL of receiver solution [TM with or 
without inhibitor (verapamil or HM-30181A)] was added to the basolateral 
side. Samples (500 μL) were collected from the basolateral side and the fresh 
solution replaced to the basolateral compartment. To study the transport of 
compounds from the basolateral side to apical side, donor solution (1.5 mL) 
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was added to the basolateral side while 0.5 mL of the receiver solution was 
added to the apical side. In this study, samples (300 μL) were collected from 
the apical side and the fresh solution replaced to the apical compartment. All 
samplings were carried out at every 30 min intervals for 2 h while maintaining 
the temperature of 37℃ and the atmosphere of 5% CO2. Aliquots of the 
sample (100 μL) were vortex-mixed with 200 μL of acetonitrile for 10 min, 
and the mixture centrifuged at 16,100 g at 4℃ for 5 min. The supernatant was 
transferred and stored at -20℃ until the analysis by LC-MS/MS (for M6) or 
liquid scintillation counting (low / high permeability marker).
2.4 Intestinal Transport and Metabolism of Indinavir in Ex Vivo
To determine the transport and metabolism of indinavir in the 
intestine in ex vivo conditions, Ussing chamber study was carried out, similar 
to the method described previously (Boisset et al., 2000; Li et al., 2002; 
Haslam et al., 2011). Briefly, a 10 cm segment of the ileum was carefully 
dissected from anesthetized rats and the excised tissue was immediately added 
to freshly prepared TM (4˚C) with O2/CO2 (95:5) bubbling. The ileum 
segment was cut into four to five 2 cm pieces to avoid Peyer’s patches and the 
cylindrical segments were cut along the mesenteric border line to expose the 
luminal side. The rectangular tissue piece was then mounted on the half of a 
１６
diffusion chamber with six fixing pins: The serous membrane was then 
removed immediately after the fixation. After the assembly of two halves of 
the chamber, 2 mL of TM (with or without 100 μM HM-30181A) was added 
to each compartment and the device pre-incubated for 20 min with carbogen 
bubbling at 37℃.
In this study, the tissue having the TEER of at least 95 Ω∙cm2 (viz, the 
resistance measured just prior to the mounting) was used. After the 
equilibration for 20 min, the medium was removed and replaced with 2 mL of 
pre-warmed TM to the receiver side / 2 mL of pre-warmed TM containing 5 
μM indinavir to the donor side. When it was necessary to study the effect of 
HM-30181A, the inhibitor at 100 µM was added to both sides. The tissue was 
incubated with carbogen bubbling at 37℃ and samples (100 μL) were 
collected every 30 min intervals from both sides of chamber up to 2 h. Upon 
completion of the incubation, the mounted tissue was washed ten times with 1 
mL of ice-cold TM. The tissue was, then, collected and homogenized for 1 
min with a sonic dismembrator in 4-fold weight of TM and ice-cold 2 N 
NaOH solution (50:50, v/v). The homogenate was added with acetonitrile (1:3, 
v/v, 200 mL of total volume) containing glipizide (100 ng/mL) and the 
mixture vortexed-mixed for 10 min. The mixture was centrifuged at 16,100 g 
at 4℃ for 5 min, and the supernatant was collected / stored at -20℃ until the 
analysis for indinavir and M6.
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2.5 In vivo Studies
For intravenous administration study, previously reported method was 
used (Ahn et al., 2004; Koo et al., 2005). Briefly, rats (250~300 g) were 
anesthetized with tiletamine/zolazepam (20 mg/mL) and xylazine (4 mg/mL) 
solution at a dose of 1 mL/kg by intramuscular administration  to catheterize 
a polyethylene tubing (PE-50; Clay Adams, Parsippany, NJ) in the right 
femoral artery for blood sampling and vein for drug administration under the 
light anesthetization. Control rats (N = 5) received only the vehicle 
(DMAc:PEG400:saline = 1:2:1, v/v/v; administration volume at 2 ml/kg) 
orally in addition to a single intravenous dose of indinavir at 1 or 10 mg/kg. In 
this control study, the vehicle was administered 10 min before the injection. 
The drug was injected (injection volume at 1 mL/kg) as a solution in 0.05 M 
citric acid. At pre-determined time points (0, 2, 5, 15, 30, 60, 90 and 120 min), 
blood samples (150 μL each) were collected. For HM-30181a group, rats (N = 
4) received a single oral dose of HM-30181A at 10 mg/kg while maintaining 
other experimental conditions. 
For oral administration study, surgical procedures and other 
administration conditions, including indinavir dosing vehicle, were identical 
to the intravenous administration study except that indinavir was given orally. 
In this study, blood samples were collected at 0, 5, 15, 20, 25, 30, 45, 60, 90 
and 120 min after the oral administration of indinavir.
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For intra-portal vein infusion study, rats were catheterized in the right 
femoral artery, vein and portal vein for blood sampling and drug 
administration. Indinavir solution was infused to rats through the poral vein 
cannulae at the rate of 62.5 μg/min for 20 min. Ten min prior to the initiation 
of the infusion, rats orally received HM-30181A (10 mg/kg) or the vehicle. 
Blood samples were collected at 0, 5, 15, 20, 25, 30, 45, 60, 90 and 120 min 
after the initiation of the infusion.
Collected blood samples were immediately centrifuged at 16,100 g 
for 10 min at 4℃, and the supernatants were collected / stored at -20℃ until 
the analysis for indinavir / M6 by LC-MS/MS (see below).
2.6 Kinetic model for ex vivo results on intestinal metabolism to 
M6 and transport of indinavir
In this study, a relatively specific P-gp inhibitor (e.g., HM-30181A) 
was used to affect the efflux process of indinavir in ex vivo studies involving 
Ussing chambers. To ascertain whether the results from the ex vivo study 
were kinetically consistent with the cooperative effect of P-gp and intestinal 
metabolism, a simulation study was carried out for the formation of M6 in the 
presence and the absence of P-gp inhibition. In this study, the kinetics of P-gp 
efflux or metabolism was assumed to follow a simple Michaelis-Menten 
kinetics using relevant pharmacokinetic parameters from the literatures (Table 
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1) (Hochman et al., 2000). In particular, a three compartment model (Fig. 1) 
was taken into consideration for the kinetics of indinavir across and in the 
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Where ID, IC, and IR are the concentration of indinavir in donor, 
intracellular, and receiver compartments, respectively; MD, MC, and MR are the 
concentration of M6 in donor, intracellular, and receiver compartments, 
respectively; VD, VC, and VR are the volume of donor, intracellular, and 
receiver compartments, respectively; PS1 and PS2 are the passive 
permeability-surface area product of indinavir between donor and intracellular 
compartment, and between intracellular and receiver compartment, 
respectively; PS1’ and PS2’ are the passive permeability-surface area product 
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of M6 between donor and intracellular compartment, and between 
intracellular and receiver compartment, respectively; CLeff and CLeff ’ are the 
efflux clearance mediated by P-gp of indinavir and M6 respectively; CLm is 
the formation clearance of M6 from intracellular indinavir. In this study, the 
receiver compartment was assumed to be under a sink condition so that the 
drug / metabolite movement from the acceptor to the tissue is practically 
negligible. For the purpose of simulation, PS1 and PS2 were assumed to be 
identical to each other, and estimated from the apparent permeability (Papp) 
obtained from the ex vivo study. 
2.7 Analytical Procedure
2.7.1. High performance liquid chromatography for RLM studies
The concentration of standard CYP substrates in RLM incubations 
was determined by HPLC-UV system (Waters e2695 HPLC, Waters 2489 UV 
system). Samples (100 μL) were added with 100 μL ice-cold acetonitrile and 
vortexed for 10 min. After the centrifugation at 16,100 g at 4℃ for 10 min, 
the supernatant was collected / transfered and 100 μL of the aliquot was 
directly injected onto a Gemini-NX 5 μ C18 (150 Ｘ 4.6 mm) column. In this 
study, the flow rate at 1 mL/min was used. For analysis of phenacetin (1A2), 
diclofenac (2C9), omeprazole (2C19) and dextromethorphan (2D6), the 
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mobile phase consisted of (A) acetonitrile and (B) phosphate buffer (20 mM). 
Linear gradient was utilized for the analysis of the substrate as mobile phase 
of (A):(B) was 20:80 to 56:44 in 6 min for phenacetin, 55: 45 to 82:18 in 6 
min for diclofenac, 30:70 to 45:55 in 3.5 min for omeprazole or 20:80 to 
47:53 in 6 min for dextromethorphan, respectively. For analysis of 
testosterone, the isocratic method was used. Mobile phase (A) and (B) were 
the mixture of acetonitrile and water in 5:95 and 80:20, respectively, and 
adjusted to pH with trifluoroacetic acid at 3.4. In this study, the flow of 
mobile phase (A):(B) was 50:50. The absorbance at 245, 254, 302, 280 or 254 
nM was monitored for the determination of phenacetin, diclofenac, 
omeprazole, dextromethorphan or testosterone, respectively.
2.7.2. Liquid chromatography-Tandem mass spectrometry assay for 
indinavir and M6
For the determination of indinavir / M6 concentrations in ex vivo and 
in vitro studies, the sample (100 μL) form Caco-2 cells study or Ussing 
chamber study was added with 200 μL acetonitrile. For the determination of 
the concentration of the drug / metabolite, in vivo samples (50 μL) were 
added with 200 μL acetonitrile containing glipizide (100 ng/mL; an internal 
standard) for deproteination. The mixture was then vortexed for 10 minutes 
and centrifuged at 16,100 g at 4℃ for 5 min. An aliquot (100 µL) of the 
supernatant was collected / transfered / injected (5 µL) onto LC-MS/MS. The 
LC-MS/MS system comprised Waters e2695 HPLC (Milford, MA) and API 
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3200 QTrap (Applied Biosystems, Foster City, CA). The mobile phases 
consisted of (A) 0.1% formic acid in acetonitrile and (B) 0.1% formic acid in 
water. The flow was performed at a flow rate of 0.3 mL/min with a gradient of 
60% mobile phase (A) for 0.5 min, 60% to 75% mobile phase (A) for 0.1 min, 
75% mobile phase (A) for 0.4 min, 75% to 60% mobile phase (A) for 0.1 min, 
60% mobile phase (A) for 3.9 min and 5 μL of sample was injected onto an 
Eclipse XDB-C18, 3.5 μm, 2.1 Ｘ 100 mm (Agilent Technologies, Santa 
Clara, CA). The samples were ionized using turbo ion spray interface in the 
positive ionization mode and monitored at the following Q1/Q3 transitions 
(m/z): 614.1/421.1 for indinavir, 523.3/273.2 for M6 and 445.8/320.9 for 
glipizide. The common source/gas of indinavir and M6 was followed. The ion 
spray voltage, source temperature and pressure of the curtain gas were 5500 V, 
500°C and 10 psi. The declustering potentials (DP) for indinavir, M6 and 
glipizide were 51, 56 and 47.5 V, respectively. The entrance potentials (EP) 
were 5.2, 5.5 and 4.02 V, collision energies (CE) were 42, 41 and 17 V and the 
collision cell exit potentials (CXP) were 6.0, 4.0 and 8.0 V, respectively. 
Calibration curves for indinavir ranged from 10 to 5000 nM for in vitro / ex 
vivo study and from 10 to 10000 ng/mL for in vivo studies, and were linear (r2
> 0.998) for all experimental conditions. In this study, the accuracy ranged 
from 88 to 108% for the indinavir assay. For the calibration curve for M6 
ranged from 5 to 10000 nM for in vitro studies, from 5 to 250 nM for ex vivo 
study and from 5 to 500 ng/mL for in vivo studies. All calibration curves for 
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M6 were found linear (r2 > 0.998), with the accuracy ranged from 88 to 113%.
2.8 Data Analysis
For RLMs inhibition studies, microsomal intrinsic clearance (CLint) of 











where Kel represents the elimination rate constant (minute
-1) and [microsome] 
represents the protein concentration in the microsomal incubation (mg/mL). 
The parameters of mg microsomal protein/g liver and g liver/kg body weight
was obtained from the literature (Houston, 1994; Bayliss, 1999; Naritomi et 
al., 2001).
When it was necessary to determine M6 permeability, the apparent 
permeability (Papp) of M6 in Caco-2 cell monolayers and indinavir across the 
rat intestinal tissue in ex vivo studies were calculated according to eq. 6 








where Papp is apparent permeability coefficient (cm/sec), dQ/dt is the flux 
(μg/sec), S is the surface area of the culture insert (cm2) or tissue (cm2) and C0
is the initial concentration of M6 in the donor side.
For the calculation of the efflux ratio of M6 in Caco-2 cell 
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where ER represents the efflux ratio, Papp, B to A apparent permeability from 
basolateral side to apical side, and Papp, A to B apparent permeability from apical 
side to basolateral side.
For the kinetic analysis of the plasma concentration versus time data 
for indinavir and M6, standard moment analysis was carried out by using the 
WinNonlin software (Ver. 3.1; Pharsight, Mountain View, CA, USA) running 
on a PC. The area under the indinavir and M6 concentration in the plasma-
time curve from time zero to infinity (AUCinf) and the area under the 
respective first moment–time curve from time zero to infinity (AUMCinf) were 
calculated by the linear trapezoidal method and the standard area 
extrapolation method (Gibaldi et al., 1982). The mean residence time (MRT) 
was calculated AUMCinf divided by AUCinf. In this study, systemic clearance 
(CL), half-life (T1/2) and steady-state volume of distribution (Vss) were also 
calculated assuming the first order kinetics for indinavir and M6. When 
necessary, the maximum indinavir concentration (Cmax) and the time point at 




3.1 Interaction of HM-30181A with CYP-mediated Metabolism in 
RLMs and with Uptake Transporters in Transporter-
expressing MDCKII/FRT Cells
The amount remaining (in percent of the initial amount) for each 
substrate [i.e., phenacetin (1A2), diclofenac (2C9), omeprazole (2C19), 
dextromethorphan (2D6) and testosterone (3A4)] was about 80, 90, 25, 29 and 
13% of at the last sampling time [i.e., 0, 20, 40 and 60 min (1A2); 0, 5, 10 and 
15 min (2C9, 2C19 and 2D6); 0, 5 and 10 min (3A4)]. There was no statistical 
difference in amount remaining at the last sampling time between the control 
and HM-30181A group (Fig. 2). As a result, there was no statistical difference 
in intrinsic clearances in microsomes for each substrate between the two 
groups (Table 2). The uptake of the substrate (E3S for rOatp1b2 and rOat3, 
PAH for rOat1 or MPP+ for rOct2) in the corresponding transporter-
expressing MDCKII/FRT cells was 23.0 ~ 91.4% deceased by the presence of 
their representative inhibitors (atorvastatin, probenecid and diphenhydramine) 
when compared with that of the control (i.e., no inhibitor). In contrast, the 
presence of HM-30181A did not affect the cellular uptake of the substrates in 
transporter-expressing MDCKII/FRT cells (Fig. 3). These results suggest that 
HM-30181A has no inhibitory effect on CYP-mediated metabolism and on 
SLC transporter-mediated transport.
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3.2 Bi-directional Transport Study of M6 in Caco-2 Cell 
Monolayers
In this study, bi-directional transport study of M6 was examined with 
or without HM-30181A or verapamil in Caco-2 cell monolayers. In this 
experimental system, the apparent permeability for [14C] mannitol (i.e., a low 
permeability marker), metoprolol (i.e., a high permeability marker) and [3H] 
digoxin (i.e., a standard P-gp substrate) 2.26 ± 0.14, 26.3 ± 1.1 and 4.42 ± 
0.33 x 10-6 cm/sec for transport from the apical side to basolateral side in 
Caco-2 cells, respectively. The transport permeability in the reverse direction 
(from the basal side to the apical side) was 2.40 ± 0.10, 30.5 ± 1.2 and 18.9 ± 
1.0 x 10-6 cm/sec for the three reference compounds, respectively. As a result, 
estimated efflux ratio was 1.06, 1.16 and 4.28 for mannitol, metoprolol and 
digoxin, respectively. Under this experimental condition, the apparent 
permeability of the transport of M6 from the apical to basal side of Caco-2 
cells was 36.5% increased by HM-30181A while there was no change in the 
transport by verapamil. For the case of the transport in the reverse direction 
(i.e., from the apical to basolateral side), the M6 transport was 54.3 and 66.3% 
decreased by HM-30181A and verapamil treatment, compared with that 
without the inhibitor (Fig. 4). The efflux ratio of M6 was 3.23 without the 
inhibitor and the value decreased to 1.08 by HM-30181A treatment and to 
1.03 by verapamil treatment. These observations suggest that M6 has low 
permeability, probably by the action of efflux transporter(s) such as P-gp.
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3.3 Inhibitory Effect of P-gp Inhibition by HM-30181A on 
Absorption and Metabolism of Indinavir in Rats
When pretreated with HM-30181A, the systemic exposure of 
indinavir was approximately 34% increased after intravenous injection dose 
of 1 mg/kg (Fig. 6A; Table 4). However, the M6 was below the quantification 
limit of the assay, so that the pharmacokinetics analysis could not be 
attempted. When the intravenous dose of indinavir was adjusted to 10 mg/kg, 
the systemic exposure of indinavir, as well as the formation of M6, was not 
affected (i.e., AUCM6/AUCindinavir was 4.60 ± 0.41 and 4.72 ± 1.88% in the 
absence and presence of HM-30181A) by the administration of the inhibitor 
(Fig. 6B; Table 4). For the case of the oral administration of indinavir, the 
systemic exposure was approximately 2-fold increased (p < 0.05) for both 
indinavir and M6: Cmax of indinavir was similarly increased (p < 0.05, about 
2.5-fold) by HM-30181A co-administration (Fig. 6C; Table 4). As a result, the 
AUCM6/AUCindinavir was not statistically different (i.e., 10.5 ± 1.4 and 9.95 ± 
1.8% for the control and HM-30181A treatment) between the two groups. 
However, the AUC ratio of the oral administration study was approximately 
twice the AUC ratio from the high dose intravenous injection study. These 
results suggest that inhibition of intestinal and hepatic P-gp by HM-30181A 
leads to a similar increase in the absorption of indinavir and formation of M6. 
When indinavir was infused to portal vein infusion for 20 min, the profile of 
the plasma concentration of indinavir in the systemic circulation showed clear 
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distinction 45 min of the indinavir infusion (Fig. 6D) by the administration of 
HM-30181A. The AUC of indinavir and M6 was approximately 2.5- and 1.9-
fold increased (p < 0.05) by HM-30181A, respectively, whereas Cmax of 
indinavir and M6 was not apparently affected by the inhibitor (Table 4). 
Accordingly, the AUCM6/AUCindinavir was statistically different (p < 0.05) 
between the two groups (i.e., 6.12 ± 0.32 and 4.79 ± 0.52% for control and 
HM-30181A groups), indicating hepatic elimination (e.g., biliary excretion) of 
indinavir/M6 was affected by HM-30181A.
3.4 Transport of Indinavir and Formation of M6 in Ussing 
Chambers
When the intestinal tissue was pre-treated with HM-30181A, the 
apparent permeability of indinavir was 52.3% increased compared with the 
control (Table 5). Under this experimental condition, the M6 concentration in 
the receiver and donor side was below the quantification limit of assay. The 
accumulation of indinavir in intestinal tissue tended to increase by the 
inhibitor pre-treatment although statistical different was not noted in the 
experiment (Table 5). In contrast, the amount of M6 in the intestine was 40.8% 
increased by the pretreatment (Table 5). The increased amount of M6 in the 
intestinal tissue was consistent with a kinetic model assuming an interplay 
between P-gp mediated recycling and intestinal metabolism of indinavir (Fig. 
5). These observations indicate that the inhibition of intestinal P-gp by HM-
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30181 leads to an increase in the apparent permeability of indinavir and the 
formation of M6 in the tissue.
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4. Discussion
Indinavir, a protease inhibitor for anti-retroviral therapy, was 
originally developed in 1990’s (Dorsey et al., 1994; Lin et al., 1995; Lin, 1999)
and is a well known substrate for both P-gp and CYP3A4. In particular, the 
anti-viral drug is almost metabolized by one major metabolic enzyme, 
CYP3A4, during its elimination process (Chiba et al., 1996; Lin et al., 1996; 
Chiba et al., 1997). The drug is also reported to possess a high efflux ratio, 
rendered by the action of P-gp (Kim et al., 1998; Rouquayrol et al., 2002; 
Balimane et al., 2004; Varma et al., 2005). Therefore, this drug would undergo 
a significant recycling during its intestinal absorption. Indeed, indinavir has 
been regarded as an attractive model drug for the study of the interplay 
between the recycling and intestinal first pass effect (Lin et al., 1999b). HM-
30181A, the P-gp inhibitor used in this study, does not appear to affect CYP-
mediated metabolism (Fig. 2) nor the activities of SLC transporters (Fig. 3), 
suggesting that the inhibitor is selective for P-gp (Paek et al., 2006a; Paek et 
al., 2006b; Paek et al., 2007; Kwak et al., 2010) and is useful in the study of 
the interplay between P-gp mediated efflux and intestinal metabolism.
To study the effect of the efflux on the intestinal first pass metabolism, 
the pharmacokinetics of indinavir and M6, the major metabolite, was studied 
in the presence and the absence of HM-30181A in rats. It was found that the 
pretreatment with the inhibitor led to comparable increase in the AUC for the 
drug and the metabolite: The ‘metabolic ratio’ (i.e., the AUC ratio) was 
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apparently not affected by the inhibitor treatment (Table 4) in this in vivo 
study. Therefore, this observation could be potential indication for the absence 
of the interplay effect. However, to confirm the lack of the effect, the 
possibility of ‘masking’ has to be ruled out. That is, unchanged exposure of 
dual substrates for P-gp and the metabolizing enzyme by P-gp inhibitor 
treatment or in P-gp gene knock out mice has been previously attributed to the 
‘masking effect’ rendered by the saturation of the hepatic P-gp. Therefore, 
additional in vivo studies with the intravenous administration of indinavir 
were found necessary.
The plasma concentrations of indinavir were slightly increased by 
HM-30181A at the intravenous indinavir dose at 1 mg/kg. However, the M6 
concentration was not detectable probably because of the indinavir dosage 
was not sufficient. When the indinavir dosage was increased, the AUCs for 
the drug and the metabolite were not affected by HM-30181A pretreatment at 
the intravenous indinavir dose at 10 mg/kg (Fig. 6B, Table 4), suggesting that 
the ‘masking’ effect may not be adequately ruled out in the higher dosage. 
Furthermore, it is also possible that the dosage of HM-30181A is not 
sufficient for the P-gp inhibition in the canalicular membrane. To examine this 
possibility, the concentration of HM-30181A in the blood and the liver was 
measured after the oral administration. We found that the inhibitor was not 
detected in the plasma while the liver concentration was readily measured [i.e., 
38.1 ± 15.3 and 505 ± 124 nM at 30 and 130 min after the inhibitor 
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administration, respectively (Appendix A)]. Based on the literature reports, it 
was estimated that, after 30 min of the inhibitor administration, the hepatic P-
gp would have been inhibited (Kwak et al., 2010).
To rule out the possibility of masking effect, portal vein infusion 
study was carried out. In this study, we were particularly interested in the 
range of indinavir concentration achieved by this administration condition so 
that the range obtained here would be comparable to that from the oral 
administration study. We found that a statistical difference was noted for the 
AUC of indinavir and M6 between the two groups (Fig. 6D, Table 4). In 
particular, the AUC was 2.5- and 1.9-fold higher (p < 0.05) for the drug and 
the metabolite, respectively, by HM-30181A treatment, suggesting that the net 
metabolite formation during the intestinal metabolism would be higher by the 
inhibitor treatment (Table 4). It was also found from in vitro experiment with 
Caco-2 cells that the efflux ratio for M6 was 3.23 and the value decreased to 
1.08 by P-gp inhibition, suggesting that the metabolite is also subjected to P-
gp mediated efflux. In previous studies, the efflux ratio for indinavir was 7 ~ 
15 in Caco-2 cells (Rouquayrol et al., 2002; Balimane et al., 2004; Varma et 
al., 2005). 
To further confirm the interplay effect on M6 formation by intestinal 
P-gp, ex vivo studies with Ussing chambers were carried out. As expected, the 
apparent permeability was increased for the indinavir transport across the 
intestinal tissue by the inhibitor treatment (p < 0.05) (Table 5). Interestingly, 
３３
the increased permeability was associated with no difference in indinavir 
amount in the tissue while the M6 amount in the tissue was slightly but 
distinctly increased (p < 0.05). For the case of M6 in the donor and the 
receiver, the concentration was not detectable. These results supported the 
result of oral administration study in that the action of the intestinal P-gp may 
render a decrease of the metabolism to M6 during the intestinal absorption of 
indinavir.
In summary, HM-30181A had no appreciable effect on major drug 
metabolizing enzymes nor on typical SLC transporters. In Caco-2 cell 
monolayer study, M6 has a low permeability (i.e., 0.586 ± 0.039 x 10-6
cm/sec), which could be due to a potential substrate to efflux transporter(s) 
(i.e., efflux ratio of 3.2) such as P-gp. Only a minor increase in the ‘metabolic 
ratio’ was noted after the simultaneous administration of indinavir and HM-
30181A orally. Interestingly, however, intraportal vein administration of 
indinavir led to a decrease in the ‘metabolic ratio’ of M6 by oral HM-30181A. 
Taken together, a small increase in the formation of M6 in the intestine may 
have occurred by the presence of the P-gp inhibition. In Ussing chamber 
experiment, the amount of M6 in the intestine was found to be increased by 
the pretreatment of HM-30181A, in support of the enhanced effect found in 
vivo. Therefore, these observations collectively suggest that ‘P-gp mediated 
recycling’ decrease metabolic ratio, although not to a substantial extent, in rats.
３４
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Summary of the model input parameters. In this study,    value of rat 
enzyme (Cyp3a) was assumed to be comparable to that of human enzyme 
(CYP3A4)(Hochman et al., 2000). MPPGG (i.e., milligram protein per gram 
gut) was considered to be 15.5 in this study.
Parameters Units Values
     cm/s 4.34 x 10
-6
  cm2 0.636
   ,     mL/min 3.31 x 10
-4
   μM 2.5











Elimination rate constant and apparent clearance of CYP substrates in the 
presence and the absence of HM-30181A in rat liver microsomes (n = 4)
Kel, elimination rate constant; CLint, microsomal intrinsic clearance
Phenotype Substrate
Control (+) HM-30181A
Kel CLint Kel CLint
min-1 mL/min/kg min-1 mL/min/kg
1A2 Phenacetin 0.0035 ± 0.0006 12.6 ± 2.1 0.0038 ± 0.0005 13.5 ± 1.8
2C9 Diclofenac 0.0247 ± 0.0006 88.8 ± 2.1 0.0237 ± 0.0025 85.2 ± 9.1
2C19 Omeprazol 0.0940 ± 0.0026 338 ± 10 0.0923 ± 0.0031 332 ± 11
2D6 Dextromethorphan 0.0830 ± 0.0053 299 ± 19 0.0783 ± 0.0022 282 ± 8
3A4 Testosterone 0.213 ± 0.031 716 ± 55 0.209 ± 0.029   752 ± 105
４５
TABLE 3









rOatp1b2 [3H] estrone-3-sulfate 123 ± 25 64.6 ± 14.1
rOat1 [3H] ρ-aminohippuric acid 105 ± 10 17.9 ± 5.1
rOat3 [3H] estrone-3-sulfate 107 ± 5 55.0 ± 7.6
rOct2 [3H] 1-methyl-4phenylpyridium 102 ± 6 8.8 ± 0.3




Summary of pharmacokinetic parameters for indinavir and M6 after 
intravenous, oral and portal vein administration in the presence and the 
absence of HM-30181A co-administration in rats (n = 4 or 5)
indinavir M6
control (+) HM-30181A control (+) HM-30181A
Intravenous injection
(1 mg/kg)
T1/2 min 51.3 ± 21.1 50.7 ± 13.0
CL mL/min/kg 112 ± 16.1 82.3 ± 3.5
Vss L/kg 4.74 ± 2.33 3.48 ± 0.79
AUC min*μg/mL 9.08 ± 1.33 11.3 ± 4.1
Intravenous injection
(10 mg/kg)
T1/2 min 30.5 ± 4.1 29.5 ± 12.0
CL mL/min/kg 72.7 ± 7.2 63.4 ± 21.0
Vss L/kg 2.86 ± 0.22 2.20 ± 0.53
AUC min*μg/mL 139 ± 14 168 ± 43 6.38 ± 0.79 7.38 ± 1.38
Tmax min 15.0 ± 0.0 15.0 ± 0.0
Cmax μg/mL 0.0964 ± 0.0282 0.0992 ± 0.0280
Oral administration
(10 mg/kg)
AUC min*μg/mL 25.3 ± 2.6   53.4 ± 20.9* 2.64 ± 0.27   5.28 ± 2.13*
Tmax min 20.0 ± 0.0 17.5 ± 2.9 24.0 ± 4.2 22.5 ± 2.9
Cmax μg/mL 0.614 ± 0.083   1.51 ± 0.64* 0.0477 ± 0.0083   0.114 ± 0.048*
Portal vein infusion
(5 mg/kg)
AUC min*μg/mL 51.6 ± 14.4 127 ± 31* 3.17 ± 0.93   6.08 ± 1.51*
Tmax min 20.0 ± 0.0 20.0 ± 0.0 28.3 ± 2.9 48.3 ± 36.2
Cmax μg/mL 1.56 ± 0.31 2.22 ± 0.98 0.0882 ± 0.0124 0.109 ± 0.005
T1/2, half-life; CL, clearance; Vss, steady state volume of distribution; AUC, 
area under the curve; Tmax, time point at maximum concentration; Cmax, 
maximum concentration




Apparent permeability and accumulation of indinavir and M6 in rat intestinal 
tissue (n = 5)
Papp amount in tissue
indinavir indinavir M6
10-6 cm/sec pmole/g tissue
Control 2.85 ± 0.19 2650 ± 1130 54.9 ± 10.9
(+) HM-30181A 4.34 ± 1.08* 3290 ± 1110 77.3 ± 16.3*
Papp, apparent permeability
* p < 0.05 significance between control and HM-30181A group by two-tailed 
unpaired t
４８
Fig. 1. Kinetic model for ex vivo results on intestinal metabolism to M6 and 
transport of indinavir
４９

























Fig. 2. The amount remaining CYP substrate in percent of the initial amount 
in the last sampling time in rat liver microsomes. The activity of CYP enzyme 
was examined in the absence (open bar) and the presence (solid bar) of HM-
30181A. Values are expressed as the mean ± S.D. of n = 4
５０


































Fig. 3. Cellular accumulation of corresponding substrates in transporter 
transfected MDCKII/FRT cells. [3H] estrone-3-sulfate (E3S; rOatp1b2 and 
rOat3), [3H] p-aminohippuric acid (PAH; rOat1) and [3H] 1-methyl-
4phenylpyridium (MPP+; rOct2) were examined in the absence (open bar) 
and the presence (solid bar) of HM-30181A or reference inhibitors (diagonal 
bar; atorvastatin, probenecid or diphenhydramine). Values are expressed as 
the mean ± S.D. of n = 4. Key: * p < 0.05, ** p < 0.01 and *** p < 0.001 in 
comparison to control.
５１
Fig. 4. Apparent permeability and efflux ratio of M6 in the absence (open 
bar), and the presence of (solid bar) HM-30181A or verapamil (i.e., reference 
P-gp inhibitor; diagonal bar) in Caco-2 cell monolayers. The apparent 
permeability of M6 from the apical to basolateral side was 0.586 ± 0.039, 
0.800 ± 0.085 and 0.615 ± 0.030 x 10-6 cm/sec for control, (+) HM-30181A 
and (+) verapamil group, respectively. The apparent permeability of M6 from 
the basolateral to apical side was 1.89 ± 0.26, 0.864 ± 0.002 and 0.636 ± 
0.062 x 10-6 cm/sec for control, (+) HM-30181A and (+) verapamil group. 
Estimated efflux ratio for M6 was 3.23, 1.08 and 1.03 for control, (+) HM-
30181A and (+) verapamil, respectively. Values are expressed as the mean ± 
S.D. of n = 3. Key: * p < 0.05 and ** p < 0.01 in comparison to control.









































































Fig. 5. Simulated effect of P-gp efflux on the metabolism of indinavir in 
intestinal tissue. Symbols in the figure represents the observation in ex vivo 
studies and the lines are generated from the kinetic model (Fig 1, eq. 1~6)
５３



















































































Fig. 6. Plasma concentration of indinavir and M6 (in-set) in the absence (open 
circle) or the presence (solid square) of HM-30181A co-administration. Key: 
(A), 1 mg/kg intravenous injection; (B), 10 mg/kg intravenous injection; (C), 
10 mg/kg oral administration; (D), 5 mg/kg portal vein infusion. Values are 
expressed as the mean ± S.D. of n = 4 or 5















































































































Pharmacokinetics of HM-30181A after a single oral dose of 10 
mg/kg in rats.
The surgical procedure were described in the main text. Rats (n = 4) 
received a single oral dose of HM-30181A (DMAc:PEG400:saline = 1:2:1, 
v/v/v) at 10 mg/kg (administration volume of 2 mL/kg). Approximately 150 
μL of blood was collected at 0, 5, 10, 20, 30, 60, 90, 120, 180, 240, 480 and 
1440 min. Blood samples were immediately centrifuged at 16,100 g for 10 
minutes (4℃), and the supernatants were collected / stored at -20℃ until the 
analysis for the inhibitor by LC-MS/MS. To determine the hepatic 
concentration of HM-30181A, rats received a single oral dose of 10 mg/kg 
(n=4). The animal was then sacrificed at 10, 30 and 130 min after the dose 
and the liver was immediately dissected. The tissue was homogenized in a 2-
fold volume of DPBS with a homogenizer (Ultra Turrax model, T25, IKA 
Works, Inc., Cincinnati, OH). The tissue homogenate (50 μL) was added with 
200 μL acetonitrile for deproteination. All samples were then vortexed for 10 
minutes and centrifuged at 16,100 g at 4℃ for 5 min. The supernatant was 
collected and the aliquot (5 µL) injected onto LC-MS/MS system.  In this 
study, glipizide (100 ng/mL) was used as the internal standard and the 
compound was added to acetonitrile used for the deproteination. The mobile 
phases consisted of (A) 0.1% formic acid in acetonitrile and (B) 0.1% formic 
acid in water. The flow was delivered at the flow rate of 0.3 mL/min with a 
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gradient (i.e., mobile phase (A), 50%-0.5 min, 90%-0.6 min, 90%-1.0 min, 
75%-1.1 min, 75%-3.0 min, 50%-3.1 min, 50%-5.0 min). In this study, a 
reverse phase HPLC column [i.e., Eclipse XDB-C18, 3.5 μm, 2.1 Ｘ 100 
mm (Agilent Technologies, Santa Clara, CA)] was used. The samples were 
ionized using turbo ion spray interface in the positive ionization mode and 
monitored at the following Q1/Q3 transitions (m/z): 688.9/541.0 for HM-
30181A and 445.8/320.9 for glipizide. The common source/gas of HM-
30181A and glipizide was as follows: The ion spray voltage, source 
temperature and pressure of the curtain gas were 5500 V, 500°C and 10 psi. 
The ion source gas1 and gas2 were 30 and 40 psi, respectively. The 
declustering potential (DP) for HM-30181A and glipizide were 36.0 and 47.5 
V, respectively. The entrance potential (EP) were 5.7 and 4.02 V, collision 
energy (CE) were 30.4 and 17 V and the collision cell exit potential (CXP) 
were 7.6 and 8.0 V, respectively. Calibration standard curve of HM-30181A 
with the concentration ranging from 10 to 5000 ng/mL, and was found linear 
(R2 > 0.998) with the intra-day accuracy from 89.6 to 110%.
The plasma concentrations of HM-30181A were below the 
quantification limit of the assay. In addition, the hepatic concentration was not 
detected at 10 min after the dosing (Table AP1). In contrast, the hepatic 
concentrations of HM-30181A were 37.0 ± 16.7 and 551 ± 135 pmole/g tissue
after the 30 and 130 m of the administration respectively (Table AP1), 
suggesting that hepatic P-gp is possible for after the 30 min of the oral 
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administration.
Table AP1. Hepatic concentration of HM-30181A after oral dose of 10 






30 37.0 ± 16.7
130 551 ± 135
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7. 국문초록
소장 내의 efflux transporter인 P-glycoprotein(P-gp)는 기질이
소장에서 흡수되는 중에 ‘recycle’ 과정을 일으킬 수 있다. 이 연구의
목표는 약물이 소장에서 흡수될 때 초회통과를 겪으며 대사되는
과정 중 P-gp와 연관된 ‘recycling’의 기여도를 밝히는 것이다. P-gp 
저해제인 HM-30181A과 CYP 효소들(1A2, 2C9, 2C19, 2D6, 3A4)의
상관관계를 확인하기 위하여, HM-30181A의 존재 여부에 따라 각
CYP 효소들의 지표가 되는 기질들의 안정성을 랫드의 간
마이크로좀을 이용한 in vitro 실험에서 수행하였다. 또한 대표적인
SCL transporter들(rOatp1b2, rOat1, rOat3, rOct2)과의 상관관계를
알아보기 위하여 각 수송체가 발현된 MDCKII/FRT cell에서의 표준
기질에 대한 uptake를 HM-30181A를 병용 처리하여 확인하였다. 이
연구의 모델 물질은 P-gp와 CYP3A4의 공통 기질이자 protease 
저해제로 잘 알려진 indinavir를 선정하였다. 랫드에 10 mg/kg의 HM-
30181A를 경구로 10분 먼저 투여한 후, indinavir를 10 mg/kg의
양으로 경구 투여하였다. 간문맥 등속 주입 실험에서는 대조군과
실험군 랫드의 간문맥에 catheter를 삽입하고 이를 통하여 15 
mg/kg/h로 20분 간 indinivir를 등속 주입하였으며 저해제는 10분
먼저 경구투여하였다. HM-30181은 대표적인 CYP 효소들(1A2, 2C9, 
2C19, 2D6, 3A4)과 SLC 수송체들(rOatp1b2, rOat1, rOat3, rOct2)의
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활동에 영향을 미치지 않았다. 이를 통하여 HM-30181은 P-gp에
특정한 저해제임을 확인할 수 있었다. 경구투여 실험에서 indinavir의
Cmax (Cmax, IND)은 대조군과 실험군에서 각각 0.614 ± 0.083과 1.51 ± 
0.64 μg/mL이었다. Indinavir의 AUC (AUCIND) 또한 비슷한 결과를
나타내었다. 즉, HM-30181 처리군이 대조군보다 AUC가 약 111% 
높았다 (p<0.05). 주대사체인 M6의 AUC (AUCM6) 또한 AUCIND에서와
비슷한 경향의 증가를 보였다. 간문맥 등속 주입 실험에서는 HM-
30181 처리군에서 Cmax, IND, AUCIND, AUCM6가 각각 1.4, 2.5, 1.9배가
증가하였다. Ussing chamber 실험에서 겉보기 투과계수(Papp)는
대조군과 HM-301781을 처리한 실험군에서 각각 2.85 ± 0.19와 4.34 ± 
1.08 X 10-6 cm/sec를 나타내었다. 소장 조직내의 indinavir의 누적양은
비록 통계학적으로 유의미한 차이를 보이지 않았으나 대조군과
실험군에서 각각 2650 ± 1130, 3290 ± 1110 pmole/g tissue로 증가하는
경향을 나타내었다. M6의 누적양은 각각 54.9 ± 10.9, 77.3 ± 16.3 
pmole/g tissue로 HM-30181A를 처리한 경우 뚜렷한 증가(p < 0.05)를
보였으며, recycling과 대사를 함께 가정한 동태학 모델을 통한
simulation 결과와도 동일한 양상를 나타내었다. 따라서, indinavir의
여러 경로투여를 통한 in vivo study, ex vivo study 그리고 in silico 
study를 모두 종합해 보았을 때, HM-30181A에 의해 indinavir의
흡수와 대사는 약간 증가하는 경향을 보인다고 할 수 있다.
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Cancer chemotherapy is often associated with a host of adverse 
effects, including neutropenia. This dose limiting toxicity typically causes a 
decrease in leukocyte and neutrophil counts resulting in the incidence of 
infections such as pneumonia and sepsis in patients to be significantly 
elevated [1, 2]. As a standard therapy for this condition, granulocyte colony-
stimulating factor is administered to patients receiving chemotherapy, 
although the treatment does not fully prevent the development of fevers 
and/or infections in immunocompromised subjects, especially elderly, patients 
[3, 4].
1-Palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (EC-18), a 
monoacetyldiglyceride, was originally isolated from antlers of the Sika deer 
(Cervus nippon Temminck) [5]. Although monoacetyldiglycerides are 
typically found in food, EC-18 can now be chemically synthesized in high 
yields by reacting glycerol, palmitic acid, and linoleic acid [6]. Rockpid®, a 
functional food product, contains EC-18 as the principal ingredient and was 
recently approved by Korean FDA. A literature search indicated that the 
compound was previously reported to stimulate the proliferation of 
hematopoietic stem cells and bone marrow stromal cells in vitro/in vivo, and 
to inhibit hematogenous metastasis in of biliary cancer cells in a hamster 
model [5, 7]. Furthermore, EC-18 may modulate eosinophil chemotaxis in 
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epithelial cells, and effectively suppress neutrophilic inflammation [8, 9]. In 
short, the compound is expected to be clinically useful for controlling / 
ameliorating conditions caused by inflammations. It was recently reported that 
the United States FDA approved phase II clinical trials of EC-18 for the 
management of severe chemotherapy-induced neutropenia in patients with 
advanced breast cancer who are receiving intermediate febrile neutropenia 
risk chemotherapy.
The absorption of glycerol and glycerides, probably EC-18 as well, 
proceed via complicated mechanism(s), as evidenced by their rapid 
decomposition during the digestion / absorption processes [10]. Furthermore, 
they may also be rapidly cleared by esterase enzymes that are produced in the 
body [11], suggesting that these compounds are likely to have a low 
bioavailability and short half-life. Therefore, protective formulation(s) that 
guarantee(s) the stability in the intestine and in the body may be necessary [12, 
13]. Despite the fact a number of studies regarding the pharmacological 
mechanism(s) of EC-18 have appeared in the literature, however, the 
pharmacokinetics and the mechanisms responsible for the 
absorption/elimination of EC-18 remains unknown. Therefore, the objective 
of this study was to develop and validate an analytical methodology according 
to guidelines set by the FDA [22] for the quantification of EC-18 in plasma 
samples obtained from small animal models. We were particularly interested 
in testing the applicability of the current method to pharmacokinetic studies 
involving small animals, since these animal models are likely to be useful in 
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the early development of formulation for the compound. The findings indicate 
that the assay is capable of detecting EC-18 down to 50 ng/mL in rat and 
mouse plasma samples using only a limited sample size (50 µL), which will 
permit the method to be used in pharmacokinetic studies involving small 
animals.
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2. Material and Method
2.1. Chemicals and reagents
EC-18 (98.7% purity) and EC-18-d3 [an internal standard (IS)] were 
kindly provided by EnzyChem Lifesciences Co. (Seoul, Korea). Methanol 
(HPLC grade) and isopropyl alcohol (IPA, HPLC grade) were obtained from 
Fisher Scientific (Pittsburgh, PA). Formic acid (FA) was purchased from 
Sigma-Aldrich (St. Louis, MO). Blank rat and mouse plasma samples 
containing heparin (an anticoagulant) were obtained from Orient Bio Inc. 
(Gyeonggi-do, Korea).
2.2. LC conditions
In this study, an HPLC system [Waters e2695 HPLC system 
(Milford, MA)], consisting of a binary pump, an online degasser, an 
autosampler, a column heater, and a reversed phase HPLC column [Synergi 4 
µm Polar-RP 80 Å LC Column (150 mm × 2 mm, Phenomenex, Torrance, 
CA)] was used for chromatographic separations. The mobile phase A and B 
were composed of MeOH-IPA-FA (60:40:0.1, v/v/v) and 0.1% (v/v) FA in 
purified water, respectively. The flow rate of the mobile phase at 0.3 mL/min 
and the sample volume of 5 μ5 were used in this study. The analytical 
samples and column were maintained at 4˚C and 30˚C, respectively.
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2.3. Mass spectrometer conditions
Mass spectrometric detection was performed with an API 3200 
QTrap (Applied Biosystems, Foster City, CA), equipped with an electro-spray 
ionization (ESI) source operating in the positive-ion mode. In this study, the 
multiple reaction monitoring (MRM) method was used to detect the analytes: 
The MRM m/z transitions were monitored at 635.4→355.4 for EC-18 and 
638.4→338.4 for the IS. The ion spray voltage, source temperature and 
pressure of the curtain gas were 5000 V, 200°C and 10 psi, respectively. The 
declustering potentials for EC-18 and IS were 20 and 101 V, the entrance
potentials were 10 and 6.5 V, respectively. The collision energies were 30 and 
51 V, and collision cell exit potential were 6.0 and 4.0 V, respectively. In this 
study, data acquisition and processing were performed with the Analyst™ 
software (version 1.4.2; Applied Biosystems) running on a PC.
2.4. Standards and quality control (QC) samples
Stock solutions of EC-18 and IS were prepared in MeOH containing 
0.1% (v/v) FA at concentrations of 1000 μg/mL and 1000 ng/mL, respectively. 
A batch of EC-18 standard solutions and QC solutions was prepared by the 
serial dilution of the stock solutions with MeOH containing 0.1% FA (v/v). A 
5 μL aliquot of an EC-18 standard solution was added to 45 μL of blank rat or 
mouse plasma for the preparation of calibration standards containing EC-18 at 
50, 100, 250, 500, 1000, 2500, 5000 or 10000 ng/mL. Using a similar dilution 
６７
method, a batch of QC samples was prepared so as to have concentrations of 
EC-18 at 50, 150, 1000, and 8000 ng/mL in blank plasma. The samples were 
then processed similar to the procedure described in section 2.5 (see below).
2.5. Sample preparation
A 50 μL aliquot of plasma sample was transferred to a SafeSeal 
Microcentrifuge Tube (Sorenson BioScience, Inc., Murray, UT). A 200 μL 
aliquot of IS solution (200 ng/mL in MeOH containing 0.1% FA, v/v) was 
added to the sample, followed by vortexing for 10 min. The mixture was then 
centrifuged at 16,100 g at 4°C for 10 min and the supernatant transferred to an 
analysis vial. A 5 μL aliquot was injected onto the LC-MS/MS system.
2.6. Method validation
2.6.1. Selectivity
In this study, six lots of plasma samples from six different rats/mice 
were prepared to evaluate the selectivity of the assay. In particular, the 
presence of any interfering peak in double blank samples (i.e., samples 
without EC-18 and without IS), blank samples (i.e., blank plasma added with 




Calibration curves, in the concentration range from 50 to 10000 
ng/mL, were constructed with the ratios of the peak area of EC-18 to that of 
the IS against the EC-18 concentration in the plasma standards. The 
calibration curves were fitted using a linear regression model with intercept 
and weighing factor of 1/standard concentration for the data.
2.6.3. Precision, accuracy and dilution
Three batches were prepared on different days to determine the 
precision and accuracy of the assay. Each batch consisted of six replicates of 
QC samples at concentrations of 150, 1000 and 8000 ng/ml and LLOQ 
samples (50 ng/mL). Another batch was prepared with six replicate samples 
containing 80000 ng/mL and diluted tenfold with blank plasma to give the 
expected concentration at 8000 ng/mL. All samples were then processed 
according to the procedure described in the previous section.
The precision was determined as the percent coefficient of variation 
at each concentration. The accuracy was estimated by calculating the percent 
difference between the calculated and theoretical concentrations.
2.6.4. Matrix effect and recovery
The absolute/relative matrix effect and recoveries of EC-18 and IS 
were assessed by analyzing three sets of standards at three concentrations (i.e., 
150, 1000, and 8000 ng/mL). To determine the adequate medium for 
deproteination/extraction between MeOH and ACN, the recovery study was 
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conducted in rats and mice plasma: There was no difference in extraction 
between the solvents (Supplement 3). In subsequent studies, therefore we 
chose to use MeOH as extraction solvent. To determine the absolute matrix 
effect for EC-18 and IS, samples of blank blood obtained from six different 
rats or mice were extracted as described previously, and EC-18 and IS were 
added to the post-extraction sample to generate three concentrations (set 2). 
The mean peak areas of the analyte were compared with the mean peak areas 
from neat solutions of the analyte in a MeOH solution containing 0.1% formic 
acid (set 1). In the case of the relative matrix effect, the variability, expressed 
as precision (CV, %), in the peak areas for the analyte that had been added to 
the post-extraction samples from the blank blood of six different rats or mice 
(set 2) was determined and was considered to be the relative matrix effect [14].
The recoveries of EC-18 and IS were determined by comparing the 
mean peak areas of analytes added before extraction to the same six different 
sources (set 3) with those of the analytes added to the post-extraction samples 
from different lots of rats and mice plasma at the same three concentrations 
(set 2).
2.6.5. Stability
To determine the stability of EC-18 under typical conditions in 
laboratories, the stability of EC-18 in stock solutions was examined at room 
temperature for 6 h, in refrigerated storage conditions (4°C) for 24 h and 2 
weeks, and in two frozen conditions (–20°C and –80°C) for 2 weeks. In 
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addition, the stability of EC-18 in the QC samples (i.e., 150, 1000 and 8000 
ng/mL) was examined for four different conditions, as follows: QC samples 
stored at room temperature for 24 h, samples that had been processed (i.e., 
post-preparative stability) at 4°C for 3 days, samples that were subjected to 3 
freeze-thaw cycles, and the samples that had been subjected to long-term 
storage (–80°C) for 2 weeks. Analytes were considered to be stable when the 
measured concentrations did not deviate from theoretical concentrations by 
more than 15%.
2.7. Application to pharmacokinetic study of EC-18
To determine whether the current assay method is applicable to 
pharmacokinetic characterization studies for EC-18, the 
monoacetyldiglyceride was administered to rats / mice via intravenous or oral 
administration. In this study, the dose of EC-18 via intravenous and oral 
administration was 1 and 2000 mg/kg in rats, and 5 and 2000 mg/kg in mice, 
respectively. Male Sprague–Dawley rats, weighing 245 to 250 g, and ICR 
mice, weighing 23 to 25 g, were used in this study. Experimental protocols 
involving the animals used in this study were reviewed by Seoul National 
University Institutional Animal Care and Use Committee according to the 
National Institutes of Health Publication Number 85-23 Principles of 
Laboratory Animal Care revised in 1985. EC-18 was dissolved in saline 
containing 3% Tween 80 and the solution administrated via the intravenous 
route (volume of administration, 1 mL/kg for rats; 2 mL/kg for mice). In the 
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oral administration study, EC-18 was administrated in the original oil form 
(volume of administration, 2 mL/kg for rats; 2 mL/kg for mice). Blood 
samples (150 μL) were collected in heparinized tubes via the right femoral 
artery at 0, 2, 5, 10, 15, 30, 60, 90, 120, 240, and 480 min after being 
administered to rats. For the pharmacokinetic study involving mice, blood 
samples (200 µL) were collected via retro-orbital plexus in both the 
intravenous and oral administration study at 0, 5, 15, 30, 60, 120, 240, 360 or 
480 min and 0, 15, 30, 60, 120, 240, 360, 480, 720 or 1440 min, respectively. 
Plasma samples, obtained by centrifugation of the blood at 16,100 g for 10 
min, were collected and stored at –80°C prior to analysis. The plasma 
concentration versus time data for EC-18 was analyzed by the non-
compartmental method using the WinNonlin software (Ver. 3.1; Pharsight, 
Mountain View, CA, USA) running on a PC. The area under the EC-18 
concentration in the plasma-time curve from time zero to infinity (AUC0→∞) 
and the area under the respective first moment–time curve from time zero to 
infinity (AUMC0→∞) were calculated by the linear trapezoidal method and the 
standard area extrapolation method [16]. The mean residence time (MRT) was 
calculated AUMC0→∞ divide by AUC0→∞. In this study, a standard moment 
analysis was applied to calculate systemic clearance (CL), half-life (T1/2) and 
steady-state volume of distribution (Vss). The maximum EC-18 concentration 
(Cmax) and the time point at Cmax (Tmax) were read directly from the time-
concentration profile of EC-18 in the plasma.
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3. Results and Discussion
3.1. Mass spectrometry and Chromatography
The chemical structures of EC-18 and EC-18-d3 (i.e., the IS) are 
depicted in Fig. 1. The m/z values of EC-18 and IS were detected at 635.4→
355.4 and 638.4→338.4, respectively (Fig. 1). An optimized chromatographic 
run time of 7 min per sample yielded symmetrical peaks for both analytes 
with an adequate separation between them and from other interfering peaks 
(Fig. 2). Based on these observations, the chromatographic conditions that 
resulted in retention times of 5.2 min for EC-18 and IS were selected. This 
spectrometric and chromatographic conditions were used in subsequent 
studies
3.2. Specificity, lower limit of quantification and linearity
EC-18 and IS were readily separated from the other peaks identified 
the double blank matrix under the LC–MS/MS conditions used (Fig. 2). 
Additionally, chromatograms, obtained from six different lots of blank 
analyses, indicated that no interfering peak was apparent in the vicinity of the 
analyte peaks (Fig. 2 and Table 1), suggesting that the assay has adequate 
specificity for quantitating EC-18 and IS in rat and mouse plasma samples. At 
the lower limit of quantification (LLOQ) level (i.e., 50 ng/mL) for EC-18, the 
precision (CV) of the peak area was 6.3 and 7.1% in rat and mouse plasma, 
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respectively (Table 1), with the signal to noise ration of at least 5 at LLOQ. 
The linearity of EC-18 in rat/mouse plasma samples, as estimated from five 
separate runs of calibration curves, was adequate, as evidenced by a 
correlation coefficient of at least 0.999 (Table 2) in the range of concentration 
of EC-18 from 50 to 10000 ng/mL.
3.3. Accuracy, precision, and sample dilution
Quality control (QC) samples, consisting of four concentration levels 
of EC-18 at 50, 150, 1000, and 8000 ng/mL in the rat and mouse plasma, were 
analyzed in six replicates to determine intra-day accuracy (RE) and CV. In the 
QC samples for the rat and mouse, the RE for EC-18 ranged from –4.4 to 10.4% 
and from –2.8 to 4.8% respectively, and the CV ranged from 5.5 to 10.1% and 
from 5.8 to 9.9%, respectively (Table 3). In this study, the inter-day validation 
parameters also were estimated using six QC replicates at the four 
concentration levels on five different days. The RE and CV for EC-18 ranged 
from –4.0 to 12.0% and from 5.3 to 9.7% in the rat plasma and ranged from –
4.0 to 2.0% and from 6.4 to 13.9% in the mouse plasma, respectively (Table 
3).
In some pharmacokinetic studies, a concentration exceeding the 
upper limit of quantification may occur, and the diluting of the sample with 
blank matrices may become necessary. To determine the feasibility of such a 
dilution, a set of plasma samples was prepared that contained an EC-18 
concentration at 80000 ng/mL (i.e., 8 times the upper limit of the assay) and 
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diluted tenfold with blank plasma. The calculated concentration was found to 
be 8110 ng/mL with a CV of 2.4% and 8140 ng/ml with a CV of 7.4% in 
samples from rats and mice, respectively (Table 3), suggesting that plasma 
samples with concentration exceeding the upper limit of the assay may be 
diluted prior to the analysis.
3. 4. Matrix effect and recovery
In this study, the matrix effect and recovery of the assay were also 
estimated. QC plasma samples containing EC-18 (150, 1000, and 8000 ng/mL) 
were prepared using six different rats and mice, the samples were processed 
according to the procedure and the mean peak areas of the analytes 
determined. This absolute matrix effect for EC-18 and IS ranged from 87.6 to 
89.0% and from 87.7 to 91.9% in rat QC samples and ranged from 77.9 to 
83.4% and from 78.7 to 82.5% in mouse QC samples, respectively (Table 4), 
indicating that the matrix (i.e., plasma) suppresses the ionization of EC-18 
[15]. In addition, the relative matrix effect was estimated by directly 
comparing the peak areas corresponding to EC-18 and IS that had been added 
to post-extracted blank plasma (from six different rats/mouse) (set 2). The CV 
for the peak area for EC-18 and IS in set 2 ranged from 2.9 to 4.1% and from 
3.2 to 3.5% in the case of the rat QC samples and ranged from 3.4 to 5.4% 
and from 3.4 to 3.7% in mouse QC samples, respectively (Table 4). The CV 
for EC-18 and IS in set 1 (i.e., methanolic solution containing the analyte) 
ranged from 3.4 to 6.5% and from 2.7 to 4.3% for the validation study in rat 
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plasma samples and ranged from 2.9 to 3.4% and from 2.8 to 3.3% for the 
validation study for the mouse plasma samples, respectively (Table 4). These 
observations indicate that the variabilities of the analytes for set 1 (i.e., 
methanolic solution of the analytes) and set 2 (i.e., analytes added to post-
extracted blank plasma) were comparable. The CV for the ratio of the peak 
areas of EC-18 to that of IS ranged from 0.7 to 1.6% and from 0.2 to 2.8% for 
the set 2 sample from the rat and the mouse, respectively, and from 1.4 to 5.8% 
and from 0.5 to 2.5%, respectively, for set 1 samples. Collectively, these 
observations indicate that the relative matrix effects for EC-18 and IS are 
negligible in the current procedure. On the other hand, the overall recovery of 
EC-18 and IS ranged from 41.0 to 53.2% and from 72.2 to 80.1% in rat QC 
samples and from 33.0 to 43.0% and from 63.7 to 65.8% in mouse QC 
samples, respectively (Table 4). Despite the fact that the recovery of EC-18 
was comparatively low, the variability in the recovery was small (i.e., less 
than 12.2%) for the current method. In addition, the precision of the assay was 
consistently less than 10%. Considering the fact that the assay is 
straightforward (i.e., the plasma is extracted with MeOH) and rapid (i.e., 
theoretically up to 180 runs in a day can be performed), the present assay may 
be practically useful, especially in pharmacokinetic studies. 
3.5. Stability
The stability of EC-18 in the stock solution at a concentration of 500 
ng/mL was studied for storage at room temperature for 6 h, in refrigerated 
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conditions (4°C) for 24 h / 2 weeks, and in two frozen conditions (–20°C and 
–80°C) for 2 weeks with six replicates each (Table 5). The concentration of 
the stored sample was found to be 100.9% at room temperature for 6 hours. 
The concentrations of the stored samples were found to be 98.7 and 98.3% in 
refrigerated conditions (4°C) for 24 hours and 2 weeks, respectively. After 
maintaining frozen conditions for 2 weeks at –20 and –80°C, the sample 
concentrations were found to be 97.4 and 99.6% of the initial concentration, 
respectively. Collectively, the stability of the stock solution was deemed to be 
adequate for the storage conditions listed.
When QC samples, consisting of three concentration levels at 150, 
1000 and 8000 ng/mL, were allowed to stand at room temperature for 24 h, 
the calculated concentrations were 150, 999 and 7920 ng/mL and 149, 1040 
and 8140 ng/mL in rat and mouse QC samples, respectively (Table 6). 
Similarly, a post-preparative stability study indicated that the concentrations 
found in the samples are 97.1, 93.1 and 97.7% and 95.3, 104.7 and 98.7% of 
the theoretical values in rat and mouse QC samples, respectively (Table 6). 
For the case of a repeated freeze-thaw process, three cycles of freeze-thawing 
had a minor effect on the stability of EC-18 as evidenced by the fact that three 
concentrations of the QC samples were 88.7, 90.2 and 92.5%, and 89.8, 92.5 
and 93.5% in rat and mouse QC samples, respectively (Table 6). The long-
term storage of rat plasma samples at –80°C appeared to be adequate in terms 
of stability, since the estimated concentration was close to the theoretical 
values (i.e., differences of –5.1, –7.4 and –2.3% and –5.6, –6.8 and –1.3% in 
７８
rat and mouse QC samples, respectively, Table 6). Therefore, these 
observations indicate that EC-18 is stable under typical conditions and that the 
processing/storage conditions have no significant effect on the estimation of 
EC-18 concentrations in rat and mouse plasma samples.
3.6. Applicability in pharmacokinetic studies
To determine whether the current assay may be applied to a 
pharmacokinetic study of EC-18 in small animals such as the rat and mouse, 
the monoacetyldiglyeride was administered to rats/mice via two typical routes 
and the concentration in the plasma determined. The mean concentration time 
profile for EC-18 is shown in Fig. 3 for intravenous administration study at a 
dose of 1 mg/kg in rats and 5 mg/kg in mice. The mean concentration time 
profile for EC-18 is shown in Fig. 3. The concentrations of EC-18 were 
readily measurable in all plasma samples in both animal models after the 
intravenous administration, suggesting that the current assay is adequate for 
determining the distributive and eliminatory characteristics of EC-18 in the 
body. The calculated pharmacokinetic parameters, including T1/2, Cl, AUCinf, 
MRT and Vss, are listed in Table 7. In general, the compound appeared to 
have a limited distribution space while being cleared rapidly in the small 
animal models.
In the case of the oral administration study at a dose of 2000 mg/kg 
in rats and mice, however, the exposure of EC-18 was very low in mice 
(AUCinf was 4.23 h · μg/mL) and was generally not measurable, except for a 
７９
few time-points in rats (Fig. 3, Table 7). Assuming that the extent of 
absorption of 0.034% in mice is applicable to rats, the concentration predicted 
by physiologically based pharmacokinetic modeling (Supplementary Material 
Fig. S1) in the vicinity of Cmax would be approximately 1.09 µg/mL. 
Furthermore, the drug concentration should have been detected (LLOQ of the 
assay of 50 ng/mL) for up to 8 h after its administration (Supplementary 
Material Fig. S1) if the pharmacokinetics from mice could be scaled to rats. 
Collectively, these observations suggest that a species difference exists in 
intestinal absorption, consistent with literature information on the 
absorptive/eliminatory properties of other glycerides.
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4. Discussion
An LC–MS/MS procedure for determining EC-18 levels in rat and 
mouse plasma samples was developed and validated in terms of selectivity, 
linearity, accuracy, precision, matrix effects, recovery, and stability. The 
developed method involves a simple, straightforward sample preparation and 
a rapid LC run-time (7 min), while having an acceptable sensitivity/reliability 
for pharmacokinetic studies involving EC-18. Therefore, the developed assay 
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Table 1
























1 0.0 0.0 82.6 14800 0.0 0.0 77.0 10500
2 0.0 0.0 98.2 13600 0.0 0.0 72.3 11000
3 0.0 0.0 97.8 17300 0.0 0.0 66.5 12900
4 0.0 0.0 89.0 16600 0.0 0.0 64.3 11300
5 0.0 0.0 91.2 16900 0.0 0.0 69.4 10500
6 0.0 0.0 92.0 16500 0.0 0.0 75.6 11000
Mean 0.0 0.0 91.8 16000 0.0 0.0 70.8 11200
CV (%)c) 0.0 0.0 6.3 9.0 0.0 0.0 7.1 7.9
a) Sample containing no analyte or IS, was extracted and analyzed.
b) Samole containing only IS, was extracted and analyzed.
c) CV (%) = standard deviation / mean × 100.
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Table 2
Calibration curves of EC-18 in rats and mice plasma
Run
Rats plasma Mice plasma
Slope Intercept R Slope Intercept R
1 0.000979 –0.0390 0.999 0.000443 0.0120 0.999
2 0.000817 –0.0325 0.998 0.000505 –0.00547 0.999
3 0.000885 –0.0309 0.999 0.000432 0.00988 0.999
4 0.000891 –0.0249 0.999 0.000525 –0.00880 0.999
5 0.000926 –0.00446 0.999 0.000520 0.00402 0.998
Mean 0.000900 –0.0264 0.999 0.000485 0.00233 0.999
CV (%)a) 6.8 - b) - 8.9 - b) -




Quality control sample of EC-18 in rats and mice plasma
Batch
Theoretical concentration (ng/mL)
LLOQ LQC MQC HQC HQC
50 150 1000 8000 8000a)
Rats plasma
(A) Intraday accuracy and precision (n=6)
Mean estimated concentration 55.2 143 1010 8000 8110
CV (%)b) 10.1 7.0 6.4 5.5 2.4
RE (%)c) 10.4 –4.4 1.0 0.0 1.4
(B) Inter-day accuracy and precision (n=30)
Mean estimated concentration 56.0 144 972 7930
CV (%) 9.7 5.3 9.0 6.1
RE (%) 12.0 –4.0 –2.8 –0.9
Mice plasma
(A) Intraday accuracy and precision (n=6)
Mean estimated concentration 52.0 146 1040 8380 8140
CV (%)b) 9.9 8.1 8.5 5.8 7.4
RE (%)c) 3.9 –2.8 4.0 4.8 1.8
(B) Inter-day accuracy and precision (n=30)
Mean estimated concentration 48.0 146 1020 8130
CV (%) 13.9 7.1 8.5 6.4
RE (%) –4.0 –2.9 2.0 1.6
a) Analyzed after a tenfold dilution with blank rat plasma (i.e., 80000 →
8000 ng/mL).
b) CV (%) = standard deviation for the concentration / mean concentration ×
100. 




Matrix effect, recovery, and precision (CV, %) for EC-18 and EC-18-d3






Recoveryb)(%) Precisionc) (CV, %)
EC-18 IS EC-18 IS
EC-18 IS EC-18/IS
Set 1 Set 2 Set 1 Set 2 Set 1 Set 2
Rats plasma
150 89.0 91.9 41.0 72.2 6.5 2.9 2.7 3.2 5.8 0.7
1000 88.0 89.4 48.6 73.9 4.7 4.1 3.1 3.5 4.6 1.3
8000 87.6 87.7 53.2 80.1 3.4 3.2 4.3 3.4 1.4 1.6
Mice plasma
150 83.4 81.9 33.0 63.7 3.1 5.4 3.3 3.7 0.5 2.2
1000 77.9 78.7 37.8 65.8 3.4 3.8 3.0 3.7 2.5 0.2
8000 82.3 82.5 43.0 64.6 2.9 3.4 2.8 3.4 0.6 2.8
a) Absolute matrix effect expressed as the ratio of the mean peak area of an 
analyte added post-extraction (set 2) to the mean peak area of the same 
analyte standards (set 1) multiplied by 100.
b) Recovery, calculated as the ratio of the mean peak area of an analyte added 
before extraction to the mean peak area of an analyte spiked post-extraction 
(set 2) multiplied by 100.
c) Precision of determination of peak areas of EC-18 and IS, and peak area 
ratios (EC-18/IS) in set 1 and 2 as the measure of relative matrix effect.
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Table 5
Stability of EC-18 in stock solutions
Batch













Number of samples 3 3 3 3 3 3
Mean response 2310 2330 2280 2270 2250 2300
CV (%) 6.0 6.0 3.4 6.8 3.9 7.5
Relative conc. (%) b) 100.0 100.8 98.7 98.3 97.4 99.6
a) Stock solutions were diluted to 500 ng/mL prior to analysis.




Stability of quality control samples
Batch





150 1000 8000 150 1000 8000
(A) Benchtop stability at room temperature for 24 h (n=3)
Mean estimated concentration 150 999 7920 149 1040 8140
CV (%)a) 0.4 2.9 6.5 3.0 3.5 4.4
RE (%)b) –0.2 –0.1 –1.0 –0.9 4.0 1.8
(B) Post-preparative stability at 4oC for 3 days (n=3)
Mean estimated concentration 146 931 7820 143 1050 7890
CV (%) 7.3 1.6 6.0 5.3 7.2 4.7
RE (%) –2.9 –6.9 –2.3 –4.7 4.7 –1.4
(C) Freeze–thaw stability (3 cycles) (n=3)
Mean estimated concentration 133 902 7400 135 925 7480
CV (%) 8.5 2.0 2.6 2.4 2.8 2.5
RE (%) –11.3 –9.8 –7.5 –10.2 –7.5 –6.5
(D) Long-term stability for 2 weeks (n=3)
Mean estimated concentration 142 926 7820 142 932 7900
CV (%) 8.9 4.2 4.0 6.7 7.1 3.8
RE (%) –5.1 –7.4 –2.3 –5.6 –6.8 –1.3
a) CV (%) = standard deviation of the concentration / mean concentration ×
100. 








iv injection iv injection oral administration
T1/2 h 1.25 ± 0.06 1.17
CL mL/h/kg 32.1 ± 3.3 161
AUCinf h · μg/mL 31.3 ± 3.1 31.1 4.23
MRT h 1.78 ± 0.31 1.32




Fig. 1. The structures and product-ion scan spectra of (A) EC-18 and (B) EC-




Fig. 2. Multiple reaction monitoring (MRM) chromatograms of: (A) double 
blank rat plasma, (B) rat plasma containing EC-18-d3 (IS, 200 ng/mL), (C) rat 
plasma containing EC-18 at LLOQ (50 ng/mL) and IS, (D) double blank 
mouse plasma, (E) mouse plasma containing EC-18-d3 (IS, 200 ng/mL), and 
(F) mouse plasma containing EC-18 at LLOQ (50 ng/mL) and IS.
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Fig. 3. The mean concentration time profile of EC-18. (A) Intravenous 
injection in rats (1 mg/kg), (B) intravenous injection (5 mg/mg) and ora
l administration (2000 mg/kg) in mice. Each point represents the Mean 




In this study, we conducted a series of simulation studies for the
estimation of the concentration profiles of EC-18 in the plasma of the mouse 
and rat. For pharmacokinetic calculation, Simcyp® software [1] version 15 
Release 1 (Simcyp Limited, Sheffield, UK) was used. Since     	of EC-18 in 
rats and mice were low (i.e., 58.0 and 212 mL/kg, respectively), a minimal 
PBPK model without SAC (i.e., single adjusting compartment) was 
considered adequate for estimating the distribution kinetics of the compound 
[2] and the resulting equations for the model presented as described below :
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For the gastrointestinal compartment’
    
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= −   ∙     			( 4)
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where      ,     , and     are the concentration of drug in the systemic, 
portal vein, and liver compartment, respectively;     ,     , and     are the 
apparent volume of the systemic (i.e.,     −     ), portal vein, and liver 
compartment, respectively;   ,    , and     are the hepatic, hepatic artery, 
and portal blood flow, respectively;   ,   is the liver-to-plasma concentration 
ratio (i.e., this value was arbitrarily set as unity);     is the amount of drug in 
the gastrointestinal compartment;    is the absorption rate constant;      
is the systemic clearance. When necessary, the     and systemic clearance, 
calculated from moment analysis (Table 7), were also used.
In this study, the concentration-time profile after oral administration 
of EC-18 was available only in mice: Therefore, the concentration profile in 
rats was simulated under the assumption of linear pharmacokinetics for EC-18 
and the first order kinetics in the intestinal absorption. The absorption rate 
constant    of the mouse, obtained from the data, was assumed to be 
identical to that in rats. In a preliminary study, in silico prediction of    was 
considered, although this approach resulted in unrealistic value for    in 
mice, probably because of the high lipophilicity of the glyceride thereby 
leading to unacceptable prediction (i.e., calculated log P, 11.14; MarvinSketch 
software, ChemAxon, Budapest, Hungary) (data not shown). Therefore,   
and other pharmacokinetic variables were either obtained from Parameter 
Estimation Method built in Simcyp® software or consolidated from the 
observation as described above. The list of pharmacokinetic parameters used 
９９
in the calculation was summarized in Table S1. Based on the model and the 
parameters, the predicted concentration-time profile of EC-18 in the plasma 
after intravenous administration was reasonable for the both species (Fig. S1). 
In addition, the predicted profile of EC-18 was adequate in mice. Interestingly, 
however, the calculation predicted that the concentration in the rat plasma be 
above 50 ng/mL (i.e., LLOQ of the study) from time 0.11 to 24 h in rats when 
the oral dose was given (Fig. S1) if the pharmacokinetic assumption is valid. 
Therefore, these observations indicate that there is a species-difference in 
kinetics of intestinal absorption for EC-18. This aspect of EC-18 
pharmacokinetics warrants further investigation.
Table S1
Summary of pharmacokinetic parameters for EC-18 used in the calculation for 
rats and mice




QHA mL/min 1.28 0.614
QPV mL/min 18.1 2.54
QH mL/min 19.4 3.15
VLI mL 8.57 1.19
１００
































































Fig. S1 Observed and predicted plasma concentration time profile of EC-18 
after intravenous and oral administrations in rats (Panel A) and mice (Panel B). 
Intravenous injection in rats (1 mg/kg), intravenous injection (5 mg/kg) and 
oral administration (2000 mg/kg) in mice was given to animals (indicated as 
symbols in the Figure). The line in the figure represents the concentration 
calculated using pharmacokinetic models assuming the EC-18 administrations 
[i.e., intravenous injection in rats (1 mg/kg), intravenous injection (5 mg/kg) 




[1] M. Jamei, S. Marciniak, K. Feng, A. Barnett, G. Tucker, A. Rostami-
Hodjegan, The Simcyp® population-based ADME simulator, Expert opinion 
on drug metabolism & toxicology 5(2) (2009) 211-223.
[2] Y. Cao, W.J. Jusko, Applications of minimal physiologically-based 
pharmacokinetic models, Journal of pharmacokinetics and pharmacodynamics 
39(6) (2012) 711-723.
[3] M. Fujikawa, R. Ano, K. Nakao, R. Shimizu, M. Akamatsu, Relationships 
between structure and high-throughput screening permeability of diverse 
drugs with artificial membranes: application to prediction of Caco-2 cell 
permeability, Bioorganic & medicinal chemistry 13(15) (2005) 4721-4732.
１０３
6.2. APPENDIX B
In this study, we compared the mean peak area of QC samples 
to determine the effect of plasma volume. Samples were prepared 
followed method: preparation method of QC samples of set 1 was 
described in sections 2.4 and 2.5 of the main text. Briefly, 5 μL aliquot 
of an EC-18 solution was added to 45 μL of blank rat or mouse plasma. 
A 200 μL aliquot of IS solution (200 ng/mL in methanol containing 0.1% 
FA, v/v) was added to the sample. For set 2, samples were prepared by 
adding 5 µL aliquot of an EC-18 solution and 195 μL aliquot of IS 
solution (200 ng/mL in methanol containing 0.1% FA, v/v) to 50 μL of 
blank rat or mouse plasma. All samples were vortexed for 10 min and 
centrifuged at 16,100 g at 4°C for 10 min. A 5 μL aliquot was injected 
onto the LC-MS/MS system for the analysis of EC-18.
The mean peak areas of LLOQ in set 1 and set 2 were 91.8 and 
88.8, and those of HQC were 16000 and 15300 in the rat plasma, 
respectively. For the case of the mouse plasma, the peak areas of LLOQ 
and HQC in set 1 and set 2 were 70.8, 64.9, and 11200, 10600, 
respectively. This result indicate that small difference in the sample 
composition led did not cause any statistical difference when analyzed 
by unpaired t-test for both rat/mouse plasma, and the difference in the 





Rat plasma Mouse plasma
Set 1 Set 2 Set 1 Set 2
LLOQ HQC LLOQ HQC LLOQ HQC LLOQ HQC
1 82.6 14800 85.9 13300 77.0 10500 70.1 10600
2 98.2 13600 93.3 14400 72.3 11000 57.8 9680
3 97.8 17300 93.9 15900 66.5 12900 70.5 11900
4 89.0 16600 81.9 16300 64.3 11300 64.9 10100
5 91.2 16900 86.6 16900 69.4 10500 57.6 11000
6 92.0 16500 91.1 14700 75.6 11000 68.8 10600
Mean 91.8 16000 88.8 15300 70.8 11200 64.9 10600
sd 5.8 1435 4.7 1347 5.0 890 6.0 766
CV (%)c) 6.3 9.0 5.3 8.8 7.1 7.9 9.2 7.2
Set 1, 45 µl plasma + 5 µl stock(10x) + 200 µl MeOH (0.1% FA, v/v))
Set 2, 50 µl plasma + 5 µl stock(10x) + 195 µl MeOH (0.1% FA, v/v))
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6.3. APPENDIX C
In this study, we compared the mean peak area of QC samples 
to determine the effect of extraction medium. Method of preparation for 
QC samples was described in the sections 2.4 and 2.5 of the main text. 
Briefly, 5 μL (in methanol or acetonitrile containing 0.1% FA, v/v) 
aliquot of an EC-18 solution was added to 45 μL of blank rat or mouse 
plasma. A 200 μL aliquot of IS solution (200 ng/mL in methanol or 
acetonitrile containing 0.1% FA, v/v) was added to the sample. All 
samples were vortexed for 10 min and centrifuged at 16,100 g at 4°C 
for 10 min. A 5 μL aliquot was injected onto the LC-MS/MS system for 
the analysis of EC-18.
In rat plasma, the mean peak areas of LLOQ and HQC were 
91.8 and 16000 with methanol precipitation method, while the values 
were 89.7 and 16700 with acetonitrile precipitation method, 
respectively. In mouse plasma, those were 70.8 and 11200 with 
methanol precipitation method, and 72.0 and 10600 with acetonitrile 
precipitation method, respectively. These results indicate that 
deproteination medium such as methanol or acetonitrile did not render 





Rats plasma Mice plasma
Methanol Acetonitrile Methanol Acetonitrile
LLOQ HQC LLOQ HQC LLOQ HQC LLOQ HQC
1 82.6 14800 80.9 17500 77.0 10500 70.1 10300
2 98.2 13600 99.2 15400 72.3 11000 78.8 9900
3 97.8 17300 93.9 15700 66.5 12900 79.1 10400
4 89.0 16600 88.1 19900 64.3 11300 61.1 11000
5 91.2 16900 82.1 15500 69.4 10500 69.4 9200
6 92.0 16500 93.8 16200 75.6 11000 73.3 12800
Mean 91.8 16000 89.7 16700 70.8 11200 72.0 10600
SD 5.8 1400 7.2 1700 5.0 900 6.8 1200




유효성분으로서, 특히 백혈수 감소증에 의한 염증증상을 조절하는데
유용한 것으로 보고되어 있다. 한국에서는 건강기능식품으로 허가를
받았지만, 열성 호중구 감소증을 보이는 진행성 유방암 환자를
대상으로 화학요법에 의한 호중구 감소증에 대한 임상 2상 시험을
진행중이다. 이 연구의 목적은 랫드와 마우스의 혈장에서 EC-18에
대한 빠르고, 민감한 분석방법을 개발하고 이를 약물동태학 연구에
적용하는 것이었다. 메탄올을 이용하요 랫드와 마우스의 혈장에서
EC-18을 추출하고 이를 LC-MS/MS에 주입하여 분석을 하였다.
검체와 EC-18-d3 (내부표준품)의 MRM 값은 각각 635.4→355.4,
638.4→338.4이었다. 두 종류의 혈장에서 최소정량한계는 50 
ng/mL이었으며, 검량선의 수용 가능 직선성은 50 ~ 10000 ng/mL (r > 
0.999)에서 확인하였다. 정확도, 정밀도, 희석효과, 회수율, 매트릭스
효과, 안정성과 같은 밸리데이션 파라미터는 모두 밸리데이션
가이드라인의 수용 범위 안에 들었으며, 이는 실험한
농도범위에서의 EC-18에 대한 분석 평가가 적절하였음을
말해주었다. 이에, 랫드에 1 mg/kg, 마우스에 5 mg/kg의 양으로
정맥주사를 하여 8시간 동안 실험하고, 마우스에 2000 mg/kg의
１０８
양으로 경구 투여하여 24시간동안의 혈장내 EC-18의 농도를
측정하였다. 그 결과 개발한 분석 방법은 두 동물 모델의 EC-18에
대한 약물동태학 실험을 하는데 적합한 것을 확인할 수 있었다.
주요어: EC-18; 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol; 약물동태학; 
LC-MS/MS 분석
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